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ABSTRACT 
Yasmeen Rahimi 
THE ROLE OF PYRUVATE DEHYDROGENASE KINASE IN GLUCOSE AND 
KETONE BODY METABOLISM 
 
The expression of pyruvate dehydrogenase kinase (PDK) 2 and 4 are increased in 
the fasted state to inactivate the pyruvate dehydrogenase complex (PDC) by 
phosphorylation to conserve substrates for glucose production.  To assess the importance 
of PDK2 and PDK4 in regulation of the PDC to maintain glucose homeostasis, PDK2 
knockout (KO), PDK4 KO, and PDK2/PDK4 double knockout (DKO) mice were 
generated.  PDK2 deficiency caused higher PDC activity and lower blood glucose levels 
in the fed state while PDK4 deficiency caused similar effects in the fasting state.  DKO 
intensified these effects in both states.  PDK2 deficiency had no effect on glucose 
tolerance, PDK4 deficiency produced a modest effect, but DKO caused a marked 
improvement, lowered insulin levels, and increased insulin sensitivity.  However, the 
DKO mice were more sensitive than wild-type mice to long term fasting, succumbing to 
hypoglycemia, ketoacidosis, and hypothermia.  Stable isotope flux analysis indicated that 
hypoglycemia was due to a reduced rate of gluconeogenesis.  We hypothesized that 
hyperglycemia would be prevented in DKO mice fed a high saturated fat diet for 30 
weeks.  As expected, DKO mice fed a high fat diet had improved glucose tolerance, 
decreased adiposity, and were euglycemic due to reduction in the rate of 
gluconeogenesis.  Like chow fed DKO mice, high fat fed DKO mice were unusually 
sensitive to fasting because of ketoacidosis and hypothermia.  PDK deficiency resulted in 
 vi 
greater PDC activity which limited the availability of pyruvate for oxaloacetate synthesis. 
Low oxaloacetate resulted in overproduction of ketone bodies by the liver and inhibition 
of ketone body and fatty acid oxidation by peripheral tissues, culminating in ketoacidosis 
and hypothermia.  Furthermore, when fed a ketogenic diet consisting of low carbohydrate 
and high fat, DKO mice also exhibited hypothermia, ketoacidosis, and hypoglycemia. 
The findings establish that PDK2 is more important in the fed state, PDK4 is more 
important in the fasted state, survival during long term fasting depends upon regulation of 
the PDC by both PDK2 and PDK4, and that the PDKs are important for the regulation of 
glucose and ketone body metabolism. 
 
Robert A. Harris, Ph.D., Chair 
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 1 
INTRODUCTION 
1.  Mechanisms for regulation of blood glucose levels 
1.1.  Regulation of blood glucose levels in the fed state 
Glucose is an important nutrient for the body by serving as a major energy source 
for many cells.  Maintaining blood glucose levels are crucial for different 
nutritional states.  During the well fed state, blood glucose levels rise when a meal is 
digested and the glucose is absorbed.  To reduce blood glucose levels back to normal, the 
beta cells of the pancreas secrete insulin.  Insulin increases blood flow in the skeletal and 
cardiac muscle by activating nitric oxide generation which dilates blood vessels [1-3]. 
Increased blood flow enhances glucose delivery in the muscle.  The abundance of glucose 
is removed from the circulation by the high affinity glucose transporter, GLUT4, which is 
highly expressed in muscle and fat cells [4].  Insulin stimulates glucose transport by 
GLUT4 across the cell membranes through a facilitative diffusion mechanism [5].  
Insulin binds to the insulin receptor (IR) tyrosine kinase on the surface of muscle and 
adipose cells (Figure1).  
Plasma Membrane
IR
Insulin
P IRS P PI3K
4,5P2 3,4,5P3 PDK1
AKT
AS160 P
GTP-RabGLUT4
GLUT4
 
Figure 1.  Insulin-stimulated signaling pathway leads to GLUT4 translocation. 
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This binding induces a conformational change in the receptor leading to tyrosine 
phosphorylation of insulin receptor substrate proteins (IRS) which in turn recruit an 
effector molecule, PI 3-kinase (PI3K) (Figure 1).  PI3K converts phosphatidylinositol 
(4,5) P2 to phosphatidylinositol (3,4,5) P3 known as PIP3 which stimulates the kinase 
activity  of Akt through the interaction of phosphatidylinositol-dependent kinase-1 
(PDK1) [6].  The active Akt phosphorylates the Akt 160 kDa substrate (AS160), which 
inhibits the GTPase-activating domain associated with AS160 and promotes Rab proteins 
to exchange from its GDP to GTP bound state.  Increasing the active GTP bound state 
stimulates the recruitment of intracellular GLUT4 storage vesicle to the plasma 
membrane [4].  At the cell surface, GLUT4 facilitates the diffusion of glucose down its 
concentration gradient within the muscle and fat cells.    
Insulin also promotes the storage of glucose as glycogen in liver and muscle cells 
[7].  Insulin activates glycogen synthase (GS), the enzyme that converts glucose to 
glycogen, by inhibiting glycogen synthase kinase 3 (GSK3) [8, 9] and stimulating protein 
phosphatase 1 (PPA1) [10, 11].  Dephosphorylated GS is active and catalyzes the 
formation of glycogen from glucose.  Insulin stimulated glycogen synthesis and glucose 
uptake by GLUT4  removes glucose from the circulation and reduces blood glucose 
levels to normal.  
 
1.2.  Regulation of blood glucose levels in the fasted state 
When blood glucose levels fall below normal, insulin secretion by beta cells of 
the pancreas is reduced while glucagon secretion is increased by alpha cells of the 
pancreas.  Glucagon, a counter regulatory hormone to insulin, accelerates glycogenolysis, 
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the process by which liver glycogen is broken down into glucose [11, 12].  Glucagon 
binds to the glucagon receptor on liver cells and induces a conformational change which 
leads to the activation of G coupled proteins [13].  These G coupled proteins stimulate 
adenylate cyclase which in turn increases the level of cAMP.  This second messenger 
activates protein kinase A (PKA).  Subsequently, PKA phosphorylates and activates 
glycogen phosphorylase kinase which in turn phosphorylates glycogen phosphorylase, 
leading to its activation.  Glycogen phosphorylase is the key regulatory enzyme in 
glycogen degradation.  When glycogen is broken down, glucose is made available for 
cells to maintain blood glucose levels from falling lower.  The second mechanism by 
which blood glucose levels are replenished in the fasted state is gluconeogenesis, the 
process by which cells synthesize glucose from metabolic precursors [14].   
Gluconeogenesis occurs primarily in the liver and to a lesser extent in the kidney during 
periods of fasting and starvation.  Since the brain and red blood cells are dependent on 
glucose, it is essential to synthesize glucose from precursors such as lactate, alanine, 
pyruvate, and glycerol. Although gluconeogenensis consists of eleven enzyme-catalyzed 
reactions, phosphoenolpyruvate carboxylase (PEPCK) has long been considered the most 
important regulatory enzyme [15].  Glucagon regulates the transcription of PEPCK by 
increasing cAMP which activates protein kinase A (PKA) that phosphorylates CREB 
[16].  Phospho-CREB binds to cAMP response element (CRE) and recruits the 
coactivators CBP and p300 which attract additional coactivators to initiate PEPCK gene 
transcription [17].   
Another key enzyme in gluconeogenesis is the mitochondrial enzyme, pyruvate 
carboxylase (PC).  This enzyme is highly expressed in liver and kidney but it is also 
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present in adipose tissue, pancreas and brain, showing that PC is involved in other 
metabolic pathways [18].  In the liver and kidney, PC synthesizes oxaloacetate from 
pyruvate for gluconeogenesis.  In adipose tissue, PC provides oxaloacetate for 
condensation with acetyl-CoA for formation of citrate for de novo fatty acid synthesis 
[19].  In the pancreas, PC enhances glucose-stimulated insulin release [20, 21].  In brain, 
PC is responsible for producing oxaloacetate to replenish α-ketoglutarate for the synthesis 
of glutamate, the precursor for γ-aminobutyric acid (GABA) [22, 23].  The highest 
activity of PC is found in the fasted state primarily in gluconeogenic tissues, indicating 
that pyruvate carboxylase is essential for supplying oxaloacetate for PEPCK for the 
production of glucose.  Similar to PEPCK, transcription of PC is increased by glucagon.  
Dissimilar to PEPCK, PC is subject to allosteric regulation [24].  It has been shown that 
PC is positively regulated by acetyl-CoA, enhancing the production of oxaloacetate.  
Regulating expression of PC and PEPCK is an essential mechanism for controlling 
gluconeogenesis in the fasted state to prevent blood glucose levels from falling to low 
levels.   
It has also been shown that glucose production in the liver is controlled by 
substrate supply of gluconeogenic precursors (also denoted as 3 carbon compounds), 
lactate, pyruvate, and alanine.  Metabolic flux studies in isolated hepatocytes [25] and in 
dogs [26]  have shown that limiting the supply of 3 carbon compounds reduces the rate of 
gluconeogenesis.  In summary, regulation of gluconeogenesis as well as glycogenolysis 
by various mechanisms is essential in the fasted state to maintain glucose homeostasis. 
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1.3.  Regulation of blood glucose levels by counter-regulatory hormones 
When glucose levels fall during fasting, blood levels of counter-regulatory 
hormones, glucagon, epinephrine, growth hormone, and cortisol, increase.  Epinephrine 
binds to β-adrenergic receptors and causes a conformational change, leading to activation 
of adenylate cyclase which activates cAMP.  Similar to glucagon, epinephrine stimulates 
glycogen breakdown.  Furthermore, activated PKA phosphorylates the bifunctional 
enzyme 6-phosphofructo-2-kinase/fructose-2,6-biaphosphatase (PFK-2/FBPase), 
subsequently the kinase is inactivated and the biphosphatase is activated [27, 28].  Active 
FBPase catalyzes the dephosphorylation of fructose-2,6-biaphosphate to fructose-6-
phosphate, resulting in lower concentrations of fructose-2,6-biaphosphatase, the positive 
allosteric regulator of phosphofructokinase and negative allosteric regulator of fructose-
1,6-biaphosphatase.  Reduction in fructose-2,6-biaphosphate stimulates fructose-1,6-
biaphosphatase activity and thus, promotes glucose production by the liver.  The 
induction of glycogenolysis and gluconeogenesis by epinephrine helps to restore blood 
glucose levels to normal.  
Growth hormone, another counter-regulatory hormone, decreases glucose 
oxidation and muscle glucose uptake, although the mechanism by which growth hormone 
mediates these effects remain unknown [29].  Nevertheless, increased secretion of growth 
hormone is needed for sustaining glucose homeostasis in the fasted state.  Glucocorticoid 
is an additional counter-regulatory hormone.  It restores blood glucose levels by 
promoting glucose production through transcriptional activation of key gluconeogenic 
enzymes, PEPCK and PC [15, 30].  Glucocorticoids bind to a glucocorticoid receptor 
(GR) which dimerizes to form a homodimer.  The GR complex enters the nucleus and 
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binds to the glucocorticoid response element (GRE) of the PEPCK and PC gene and 
induces PEPCK and PC transcription to promote glucose production [30].   
 
1.4.  Importance of anaplerosis and cataplerosis in regulation of blood glucose levels  
Glucose production is mediated by key gluconeogenic enzymes, PEPCK and PC, 
which in turn catalyze cataplerotic and anaplerotic reactions.  Anaplerosis is the process 
by which metabolic intermediates of the TCA cycle are replenished [31, 32].  Normally, 
the pool of TCA cycle intermediates is sufficient to sustain the carbon flux over a wide 
range, so that concentrations of TCA cycle intermediates remain constant.  However, 
many biosynthetic pathways utilize the TCA cycle intermediates as substrates.  One of 
these pathways is gluconeogenesis which uses oxaloacetate, the recycling TCA cycle 
intermediate, to produce glucose.  The process by which TCA cycle intermediates are 
disposed is termed cataplerosis.  While the major anaplerotic enzyme, pyruvate 
carboxylase, sustains the pool of oxaloacetate for the TCA cycle, the cataplerotic 
enzyme, PEPCK, utilizes oxaloacetate as substrate  in gluconeogenesis [31].  Therefore, 
anaplerosis is coupled with cataplerosis to sustain the supply of oxaloacetate for glucose 
production in the liver.  
 
1.5.  Role of PDC in maintaining blood glucose levels 
The mechanisms regulating hepatic glucose production are not solely ascribed to 
changes in key gluconeogenic enzymes but also by the availability of substrates that can 
be converted to glucose.  Regulation of substrate availability is determined by many 
factors including the pyruvate dehydrogenase complex (PDC).  PDC is a mitochondrial 
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enzyme that catalyzes the irreversible oxidative decarboxylation of pyruvate to form 
acetyl-CoA, CO2, and NADH.  In the well fed state, PDC is active and promotes glucose 
oxidation and the disposal of three carbon compounds (lactate, pyruvate, and alanine).  In 
contrast to fed conditions, PDC is turned off in the fasted state.  As a result of an 
inactivated PDC, pyruvate oxidation is inhibited and three carbon compounds are 
conserved.  Preserving these compounds is indispensable for sustaining gluconeogenesis.  
If the complex remains totally active in the starved state, pyruvate oxidation would 
deplete the three carbon compounds needed for gluconeogenesis.  
Switching between an active and inactive PDC is not only important in glucose 
production but also in transition of glucose oxidation to fatty acid oxidation as proposed 
by the Randle cycle [33].  A series of experiments in cardiac and skeletal muscle 
conducted by Randle and colleagues showed that increased fatty acid oxidation increases 
the ratio of [acetylCoA]/[CoA] and [NADH]/[NAD+], both of which inhibit PDC 
activity.  Accumulation of acetyl-CoA in the mitochondria results in increased citrate 
formation which in turn inhibits 6 phosphofructo-1-kinase (PFK-1), leading to increased 
levels of glucose-6-phosphate [34].  Glucose-6-phosphate inhibits hexokinase, leading to 
reduced glucose oxidation.  This mechanism by which fatty acid oxidation inhibits 
glucose oxidation through PDC inactivation is known as the Randle cycle.  Earlier the 
Randle cycle was proposed as a mechanism to explain insulin resistance in type 2 
diabetes since the hallmark of this disease  is increased fatty acid oxidation and reduced 
glucose oxidation [33].  However, human and rodent studies of type 2 diabetes suggest 
high concentrations of fatty acids cause insulin resistance by decreasing glucose uptake 
rather than reducing glucose oxidation [35, 36].  Increased levels of fatty acids promote 
 8 
the synthesis of diacylglycerol (DAG) and ceramide.  DAG activates protein kinase C 
(PKC) which phosphorylates and inhibits tyrosine kinase activation of the insulin 
receptor and tyrosine phosphorylation of insulin receptor substrate (IRS-1) [37-40].  
Ceramide, a sphingolipid derivative of palmitate, on the other hand, inhibits Akt/protein 
kinase B [41].  Both of these lipid derivatives turn off the insulin signaling cascade and 
prevent insulin stimulated glucose uptake, resulting in less glucose disposal and greater 
insulin resistance.  Although the current knowledge of insulin signaling producing insulin 
resistance interferences with the Randle’s cycle as possible explanation, this cycle is 
needed to explain the transition of glucose oxidation to fatty acid oxidation which is 
highly dependent on the activity of PDC.  
 
2.  Mechanisms responsible for regulation of pyruvate dehydrogenase complex  
2.1.  Regulation of pyruvate dehydrogenase complex 
The PDC is inactivated by phosphorylation by pyruvate dehyrogenase kinases 
(PDKs) and activated by deposphorylation by pruvate dehyrogenase phosphatases (PDPs) 
[42, 43].  There are four isoforms of the PDKs and two isoforms of PDPs.  The multiple 
isoforms of the PDKs and the PDPs are distinguished by differences in tissue distribution, 
specific activities toward the phosphorylation sites, kinetic properties, and sensitivity to 
regulatory molecules [44, 45].  Phosphorylation of serine residues of the E1α subunit by 
the PDKs inactivates the PDC.  Activation of the complex, on the other hand, is 
associated with a dephosphorylated state.  Beyond these regulations, the PDC activity is 
sensitive to allosteric regulations (Figure 2).  
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Figure 2.  Regulation of pyruvate dehydrogenase complex by  phosphorylation and 
allosteric effectors [46]. 
The products of the PDC reaction, acetyl-CoA and NADH, indirectly inhibit the 
activity of the complex by activating the PDKs.  A high NADH to NAD+ ratio reduces 
the lipoyl moieties of E2 while a high acetyl-CoA to CoA ratio favors the acetylations of 
the reduced lipoyl moieties of E2.  The reduced and acetylated lipoyl moieties of E2 
subunit attract the binding of the PDKs and ensure maximum kinase activity, resulting in 
a greater phosphorylation state and less PDC activity [47, 48].  The sensitivity to 
allosteric regulation by acetyl-CoA and NADH has the order of 
PDK2>PDK1>PDK4>PDK3 [44].  Meanwhile, pyruvate inhibits PDK activity by 
binding to PDK [47].  In addition, an activated state of PDC is induced by the substrates 
(pyruvate, NAD+, and CoA) of the reaction [48].  These positive allosteric molecules 
inhibit the PDKs, resulting in activation of PDC by the PDPs. 
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2.2.  Regulation of pyruvate dehydrogenase kinases expression and activity 
Allosteric mechanisms account for short term regulation of the PDKs, while long 
term regulation is achieved by altered expression of the levels of PDKs, which occurs in a 
tissue specific manner in starvation, diabetes, and cancer.  Starvation and diabetes induce 
the expression of PDK2 in liver and kidney [49] and the expression of PDK4 in heart [49-
51], skeletal muscle [52, 53], kidney [49], and liver [44, 49, 53].  Starvation and diabetes 
are marked by high levels of glucocorticoids and free fatty acids and low levels of 
insulin.  Glucocorticoids activate the glucocorticoid receptor (GR), which cooperates 
with the transcriptional factors Fork head members of the O class (FOXO)  to recruit the 
co-activators p300/CBP that catalyze histone acetylation to induce PDK4 gene expression 
[54].  Free fatty acids stimulate peroxisome proliferator-activated receptor α (PPARα) 
which in turn activates PDK4 expression [55, 56].  While fasting conditions induce the 
expression of PDK2 and PDK4 in various of tissues, the fed state suppresses this 
induction.  Insulin inhibits PDK4 transcription by activating the protein kinase B which 
phosphorylates FOXO [46, 54, 55, 57].  Phospho-FOXO leaves the nucleus and can no 
longer bind to p300/CBP which in turn can not foster acetylation of histones, resulting in 
suppression of PDK4 transcription [58].  Insulin has also been shown to repress the 
induction of PDK2 in hepatoma cells [55].  
PDK1 expression is induced in some tumors [59, 60].  Cancer cells rely on 
aerobic glycolysis to generate energy, known as the Warburg effect [61].  Survival of 
tumor cells in a low oxygen environment requires hypoxic-induced factor (HIF) signaling 
[62].  HIF induces the transcription of PDK1 in tumor cells to decrease flux through the 
PDC and promote conversion of pyruvate to lactate.  Among the four pyruvate 
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dehydrogenase kinases, PDK3 has a limited tissue distribution.  PDK3 is expressed in 
testes, kidney, and brain [44] and is not subject to long term regulation in starvation and 
diabetes.  HIF-1 induces the expression of PDK3 in some solid tumors [63].  
 
2.3.  Metabolic effect of inhibiting PDKs by dichloroacetate 
The expression of PDK2 and PDK4 are induced in diabetes while PDK1 and 
PDK3 are induced in cancer.  Since the PDKs are important in prevalent diseases, it is 
reasonable to target PDK inhibition as a therapeutic target for diabetes and cancer.  A 
well-studied PDK inhibitor is dichloroactate (DCA) which was initially proposed as a 
treatment for lactic acidosis [64, 65].  It was anticipated that DCA lowers lactic 
production by increasing PDC activity through PDK inhibition to divert pyruvate into the 
TCA cycle instead of  the synthesis of lactate.  A controlled clinical trial of DCA showed 
a marginal reduction in blood lactate levels without diminishing acidosis [66].  
Nevertheless, DCA treatment lowers the blood levels of lactate, pyruvate, and alanine in 
rats [67].  The reduction of these gluconeogenic precursors limits the rate of glucose 
production in the liver, resulting in lower blood glucose levels [64, 68].  Even though 
DCA has glucose lowering effects, DCA has been excluded for treatment of type 2 
diabetes due to conversion of DCA to toxic metabolites, glyoxylate and oxalate [69] and 
causing peripheral neuropathy [64].  Additional PDK inhibitors, 3-chloroproprionate [70] 
and AZD7545 [71-73], lowered blood glucose levels but are not being pursued clinically.    
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2.4.  Metabolic effect of knocking out PDK4 
Although PDK inhibitors lower blood glucose levels, they lack specificity for 
PDK2 and PDK4 which are induced in starvation [49].  In order to better understand the 
role of PDK2 and PDK4 in glucose homeostasis, our group generated PDK4 knockout 
(KO) mice [74] and PDK2 KO mice.  Initially, our group focused primarily on the PDK4 
KO mice.  First, we hypothesized that knocking out PDK4 would prevent the 
phosphorylation of PDC, resulting in increased PDC activity.  As anticipated, PDC 
activity was significantly increased in heart, liver, skeletal muscle, kidney, and 
diaphragm of 48 h fasted PDK4 KO mice.  In the fed state, on the hand, PDC activity was 
similar between PDK4 KO and wild-type mice, suggesting that regulation of PDC by 
PDK4 is minimal in the fed state.  As a result of increased PDC activity, pyruvate 
oxidation was enhanced in PDK4 KO mice in the fasted state.  Lower pyruvate levels 
reduce the supply of gluconeogenic precursors in the fasted state, yielding lower blood 
glucose levels in PDK4 KO mice.  In the fed state, blood glucose levels are not different 
between PDK4 KO and wild-type mice.  Reduced blood glucose levels found in PDK4 
KO mice may be the result of increased glucose oxidation in peripheral tissues.  
Diaphragms isolated from PDK4 KO mice oxidize glucose at higher rates than 
diaphragms from wild-type mice.  Lower fatty acid oxidation rate in PDK4 KO mice may 
be the result of increased glucose oxidation.  The phenomenon of increased glucose 
oxidation inhibiting fatty acid oxidation is known as the “reverse-glucose-fatty acid 
cycle”.  Indeed, the PDK4 inhibitor, dichloroacetate, also inhibits fatty acid oxidation and 
stimulates glucose oxidation in rat muscle, heart, and liver [67, 75, 76].  
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Since a significant up regulation of PDK4 occurs in type 2 diabetic humans [77], 
in genetic type 2 diabetic animal models [68], in animals fed a high fat diet [78], and in 
humans consuming a high fat diet [79], PDK4 KO mice and wild-type mice were fed a 
high fat diet rich in unsaturated fatty acids [74] and saturated fatty acids [74, 80].  On 
both diets, PDK4 KO mice had lower blood glucose levels compared to wild-type mice. 
Nevertheless, 8 months of high fat diet feeding induced hyperinsulinemia in both groups 
of mice even though body weight, percentage of body fat, and fat accumulation in liver 
and skeletal muscle were significantly lower in PDK4 KO mice compared to wild-type 
mice [80].  These findings support PDK4 as a viable target for the treatment of type 2 
diabetes. 
Although PDK4 inhibition has potential as a therapeutic target for type 2 diabetes 
due to its glucose lowering effect, our findings with PDK4 KO mice raise concern about 
side effects that may limit the use of PDK inhibitors for the treatment of diabetes.  In the 
fasted state, blood ketone bodies (acetoacetate and β-hydroxybuyrate) are elevated more 
in PDK4 KO mice than in wild-type mice.  
 
3.  Mechanism responsible for regulation of ketone body levels       
3.1.  Regulation of ketone body production 
Ketone bodies (acetoacetate and β-hydroxybutyrate) are produced by the liver to 
provide an alternative substrate to glucose for the production of energy in brain and other 
peripheral tissues during fasting.  Ketone bodies are primarily derived from fatty acids 
which are stored in adipose tissue as triacylglycerols [81].  The rate of ketogenesis, the 
process by which ketone bodies are produced, is determined by the flux of fatty acids 
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(FA) to the liver which in turn is governed by the rate of lipolysis in the adipose tissue.  
During fasting, lipolysis is enhanced when insulin levels are low and catecholamine 
levels are high, promoting the release of fatty acids from the adipose tissue [82].   
Catecholamines include the hormones ephinephrine, norepinephrine, and 
dopamine. Epinephrine increases cAMP by stimulation of β-adrenergic receptors which 
promote adenylate cyclase activity.  The second messenger, cAMP, then activates protein 
kinase A which phosphorylates hormone sensitive lipase (HSL) and perilipin, resulting in 
recruitment of HSL to the surface of the lipid droplet after removal of perilipin [83, 84].  
Phosphorylation of perilipin also promotes the activation of adipose tissue triglyceride 
lipase (ATGL) which converts triacylglycerol (TAG) to diacylglycerol (DAG) and the 
release of one free fatty acid.  On the other hand, Hormone sensitive lipase, catalyzes the 
conversion of DAG to monoacylglycerol and one free fatty acid. Although HSL is 
capable of breaking down TAG to DAG, it performs this conversion to a lesser extent 
than ATGL [85].  These free fatty acids are transported to the liver where they enter the 
mitochondria for conversion to ketone bodies with the help of a mitochondrial membrane 
protein, carnitine palmityl transferase 1 (CPT1) [86], the second point of control of 
ketogenesis.   
CPT1 is inhibited by malonyl-CoA, the product by acetyl-CoA carboxylase 
(ACC) [87].  AMP activated kinase (AMPK) phosphorylates ACC, leading to 
inactivation.  Subsequently, less acetyl-CoA is converted to malonyl-CoA [88]. 
Suppression of malonyl-CoA levels diminishes the inhibition of CPT1 and promotes the 
transport of fatty acids to the mitochondria for oxidation to acetyl-CoA.  Normally, 
acetyl-CoA combines with oxaloacetate for further oxidation to CO2 and H2O by the 
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TCA cycle.  However, if oxaloacetate levels are low and acetyl-CoA levels are high, 
acetyl-CoA is directed to the synthesis of acetoacetyl-CoA catalyzed by thiolase [89, 90].  
Acetoacetyl-CoA is further condensed with acetyl-CoA to form hydroxyl-β-
methylglutaryl-CoA (HMG-CoA) and free CoA by HMG-CoA synthase, the third key 
regulatory enzyme for ketogenesis (Figure 2) [91].  HMG-CoA is cleared by HMG-CoA 
lyase to acetoacetate (AcAc), which is converted to β-hydroxybutyrate (β-HB) by 
reduction with NADH (Figure 2) [91-93].  
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Figure 2.  Key enzymes and reactions in ketogenesis.  Reactions are shown in black 
and enzymes catalyzing the reactions are indicated in red. 
HMG-CoA synthase, is highly expressed in the liver and is induced in fasting, 
high fat feeding, and diabetes [92].  Fasting and high fat feeding elevates the levels of 
fatty acids which in turn activate the peroxisome proliferator-activated receptors (PPAR) 
[94].  This nuclear receptor forms a heterodimer with cis-retinoid receptor (RXR) and 
binds to the promoter region of HMG-CoA synthase gene to induce transcription.  
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Hepatocyte nuclear factor 4 (HNF4) represses HMG-CoA synthase by competing for the 
same binding site as PPAR [95].  Besides transcriptional regulation, HMG-CoA synthase 
is subject to succinylation, leading to inhibition of enzyme activity [96].  Succinylation is 
an important control mechanism in the fed state to reduce HMG-CoA synthase activity to 
prevent the synthesis of ketone bodies.  Glucagon has been shown to lower the 
mitochondrial succinyl-CoA content in perfused livers and isolated hepatocytes, thereby, 
stimulating ketogenesis [97].  Glucagon increases flux through HMG-CoA synthase by 
preventing inhibition by succinylation.   
 
3.2.  Regulation of ketone body utilization 
Blood levels of ketone bodies are determined by their rates of production 
(ketogenesis) and utilization (ketolysis).  Ketone bodies are synthesized by the liver but 
oxidized in heart, kidney, brain, and skeletal muscle [98].  Within the mitochondria of 
ketolytic organs, β-HB is oxidized back to AcAc in a reaction catalyzed by β-
hydroxybutyrate dehydrogenase [81].  Acetoacetate receives a CoA moiety from 
succinyl-CoA, generating AcAc-CoA in a reaction catalyzed by succinly-CoA: 3-oxo-
acid CoA-transferase (SCOT) [99].  Mitochondrial AcAc-CoA thiolase catalyzes the 
conversion of AcAc-CoA to acetyl-CoA, which enters the TCA cycle to be further 
oxidized to CO2 and H2O.  SCOT is an important enzyme in ketolysis and is induced in 
peripheral tissues and suppressed in the liver.   
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3.3.  Metabolic acidosis due to increased ketone bodies 
Increased ketogenesis and decreased ketolysis yield an increase in blood ketone 
body levels which in turn provoke metabolic acidosis.  Metabolic acidosis is a condition 
that is characterized by a fall in blood pH due to increased production of hydrogen ions 
by the body or the inability of the body to produce bicarbonate [100].  The causes of 
metabolic acidosis are lactic acidosis, ketoacidosis, renal failure, or intoxication with 
methanol, salicylate, propylene glycol, ethylene glycol, and 5-oxoproline [100, 101]. 
Lactic acidosis occurs due to increased buildup of lactic acid.  When intracellular lactate 
is released into the blood, maintenance of electroneutrality requires the release of protons. 
The accumulation of protons causes the reduction of blood pH.  Ketoacidosis, on the 
other hand, is associated with high concentrations of ketone bodies.  It occurs when the 
body produces large amounts of ketone bodies which are accompanied by protons.  While 
oxidation of ketone bodies disposes the protons, an inability to oxidize the ketone bodies 
leaves the protons in the blood while ketone bodies are excreted into the urine with 
sodium as the counter ion.  Currently, the successful treatments for metabolic acidosis 
involve the administration of sodium bicarbonate and administrating insulin to decrease 
ketone body production and enhance ketone body utilization.  
 
3.4.  Conditions leading to increased ketoacidosis 
 Ketoacidosis is highly prevalent in type 1 diabetics caused by insulin deficiency 
and abundance of counterregulatory hormones which increase lipolysis and subsequently 
ketogenesis [102].  Ketoacidosis also occurs in pyruvate carboxylase (PC) deficient 
patients [103].  PC deficiency is a very rare autosomal recessive disease, characterized by 
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impaired synthesis of oxaloacetate for TCA cycle activity [104, 105].  Decreased 
oxaloacetate availability leads to failure of the TCA cycle with diversion of acetyl-CoA 
into ketone body production [89, 90].  Other conditions such as high fat feeding and 
ketogenic diets also induce ketosis but usually without acidosis because of the regulation 
of the process [106, 107].  The ketogenic diet, featuring a diet rich in fat and low in 
carbohydrate, increases blood ketone bodies far greater than a high fat diet, a diet rich in 
fat and carbohydrates.  Since both diets contain an abundant amount of fat, the increased 
availability of free fatty acids results in increased production of ketone bodies.  Since a 
low-carbohydrate, high fat diet is one of many dietary regimens for the treatment of 
obesity, individuals on these diets need to aware of the precautions such as ketosis 
associated with it.  The body produces ketone bodies in the fasted state to be used as an 
energy source but when production rates exceed the capacity of utilization in these 
conditions, then a rise in ketone bodies can result in ketoacidosis which can be fatal.  
 
4.  Use of stable isotope tracers to study glucose and ketone body metabolism 
Production of ketone bodies and glucose is essential in the fasted state to provide 
tissues with substrates for energy production.  Although many in vitro studies have been 
conducted to understand the mechanisms by which glucose and ketone body are 
produced, in vivo studies have been limited.  In vivo measurements of the synthesis rates 
of glucose and ketone bodies can be measured by utilization of stable isotope tracers in 
metabolic flux studies.  A tracer is a compound that is chemically and functionally 
identical to the tracee, the naturally occurring compound of interest, but differs in the 
mass number due to differences in the number of neutrons.  For example, 12C is the most 
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common isotope of carbon with 98.89 % mass abundance while 13C is the less common 
with 1.11 % mass abundance.  While 12C is the naturally occurring carbon, 13C is known 
as the stable isotope.  The position within a molecule of an enriched stable isotope of 
mass 13 carbon is referred to by the appropriate carbon number.  For example, [1-13C1] 
glucose refers to a molecule of glucose in which the 1 position is labeled with carbons 
enriched with stable isotope of mass 13 and the subscript following the C refers to the 
number of specifically enriched atoms of carbon in the molecule.  
To measure in vivo production rates of glucose in mice, for example, [U-13C6] 
glucose is delivered at a constant flow rate by a subcutaneously implanted Alzet mini 
osmotic pump (Model 2001D, Alzet, Palo Alto, CA) which dispenses [U-13C6] glucose at 
a constant rate of 8 µL/hour (Figure 4).  
20
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Figure 4.  Utilization of stable isotope, [U-13C6] glucose, to determine rate of glucose 
production.  Stable isotope [U-13C6] glucose is placed into the miniosmotic pump (as 
shown in the right corner) which is subcutaneously implanted in to the mice.  After 16 h 
of continuous delivery, isotopic equilibrium is achieved and blood collected for 
measuring rate of glucose production.  
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Important for this method is the establishment of isotopic equilibrium which 
occurs when the rate of appearance of [U-13C6] glucose (inflow) is the same as the 
disappearance of the [U-13C6] glucose (outflow) at constant infusion rate.  Isotopic 
equilibrium for [U-13C6] glucose was determined by Lee and colleagues by generating an 
isotope enrichment versus time curve where the plateau in the enrichment is defined as 
the isotopic enrichment at isotopic equilibrium (Ep) [108].  Blood is collected after 16 h 
of continuous delivery of [U-13C6] glucose to the mice.  Enrichment of glucose in the 
blood is detected by GC/MS since 13C- glucose produces a separate mass signature that 
differentiates it from the molecular weight of naturally existing glucose.  The glucose 
production rate (GP) is determined by the following equation: 
GP (mg kg-1min-1) = [U-13C6] glucose infusion rate (mg kg-1min-1) 
Ep (mg [U-13C6] glucose/mg glucose) 
 
-  [U-13C6] glucose infusion rate (mg kg-1min-1) 
 
This equation was derived by making the assumption that at equilibrium, the rate 
of appearance of glucose (Ra) is the same as the disappearance of glucose (Rd) at constant 
infusion rate.  Therefore, Ra = Rd and Ra = Rd at isotopic equilibrium, where  
Ra = inflow of 12C glucose (μmol/min) 
Rd = outflow of 12C glucose (μmol/min) 
Ra = inflow of 13C glucose (μmol/min) 
Rd = outflow of 13C glucose (μmol/min) 
The equation above can be rearranged as follows: 
Ra/ Ra (inflow) = Rd/ Rd (outflow) 
13C glucose (μmol/min) (inflow) = 13C glucose (μmol/min) (outflow) 
                 12C glucose (μmol/min)                  12C glucose (μmol/min) 
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Dividing out the minute term from the numerator and denominator of the outflow 
term 
13C glucose (μmol/min) (outflow) 
                                                          12C glucose (μmol/min) 
 
gives 13C glucose (μmol)/12C glucose (μmol) which corresponds to the isotopic 
equilibrium (Ep). We can substitute Ep for outflow: 
13C glucose (μmol/min) (inflow) = Ep 
                                                                   12C glucose (μmol/min) 
Rearranging the equation yields: 
12C glucose (μmol/min) (inflow) = 13C glucose (μmol/min) (inflow) 
Ep 
 
Since 13C glucose is infused in relatively large amounts, a correction has to be 
made for the amount infused:  
12C glucose (μmol/min) = 13C glucose (μmol/min) - 13C glucose (μmol/min) 
Ep 
  
The latter equation can be used to calculate the rate of hepatic glucose production 
[12C glucose (μmol/min)] at isotopic equilibrium (Ep) from the rate of glucose infusion by 
the osmotic pump [13C glucose (μmol/min)].   
This method of metabolic flux analysis can also be utilized to determine rate of 
ketone body production.  For this purpose, mice receive subcutaneously implantation of 
mini osmotic Alzet pump containing [U-13C4] β-hydroxybutytrate.  After implantation, 
mice are fasted overnight followed by analysis of enrichment by GC/MS.  Production of 
β-hydroxybutyrate (β-HPR) can be calculated by the equation: 
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β-HPR (mg kg-1 min-1) = [U-13C4] β-hydroxybutytrate infusion rate (mg kg-1 min-1) 
Ep(mg [U-13C4] (β-hydroxybutytrate/mg β-hydroxybutytrate) 
 
- [U-13C4] β-hydroxybutytrate (mg kg-1 min-1)            [109] 
 
Isotopic enrichment of β-hydroxybutyrate at isotopic equilibrium (Ep) is obtained 
by measuring the plateau of an enrichment versus time curve. 
 
5.  Specific aims of this study  
Stable isotope tracer studies provide a useful tool for determining production rates 
of blood metabolites in the fed and fasted states.  In the fasted state, PDK4 has been 
shown to regulate blood glucose and ketone body levels.  PDK4 KO mice have lower 
blood glucose levels and increased levels of ketone bodies in the fasted state.  At the 
beginning of this study it was not known whether PDK2 deficiency had an effect on 
glucose and ketone body metabolism.  To answer this question, PDK2 KO mice were 
examined.  In addition, PDK2 KO mice and PDK4 KO mice were crossed to produce the 
PDK2/PDK4 double knockout (DKO) mice.  
Our first aim was to determine the effects of PDK2, PDK4, and PDK2/PDK4 
deficiency on glucose and ketone body metabolism in mice.  We hypothesized that the 
combined PDK2/PDK4 deficiency would have greater effects on glucose and ketone 
body metabolism as a result of greater increase in PDC activity compared to partially 
increased PDC activity in PDK2 KO and PDK4 KO mice. 
Our second aim was to determine the mechanism by which PDKs regulate blood 
glucose levels.  We hypothesized that knocking out PDK2 and PDK4 increases PDC 
activity which in turn limits pyruvate for gluconeogenesis.  Subsequently, reduced 
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substrate supply to the liver would limit the rate of glucose production by the liver.  We 
proposed that this mechanism could be tested by flux measurements with stable isotopes. 
Our third aim was to determine whether PDK2/PDK4 double knockout mice 
maintain lower blood glucoses levels in a diet-induced diabetes mouse model.  To answer 
this question, DKO mice and wild-type mice were fed a high saturated fat diet for 30 
weeks.  Our working hypothesis is that DKO mice would be protected from 
hyperglycemia by reduction in gluconeogenesis.   
Our fourth aim was to determine the mechanism by which PDKs regulates ketone 
body levels and the effects of ketogenic diet in PDK deficient mice.  We hypothesized 
that knocking both PDK2 and PDK4 would elevate ketone bodies by increasing the rate 
of ketogenesis and/or decreasing the rate of ketolysis.  To test this hypothesis, we will 
perform in vivo and in vitro studies with stable and radioactive isotopes to determine the 
rates of keogenesis and ketolysis.   
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CHAPTER I: FASTING INDUCES KETOACIDOSIS AND HYPOTHERMIA IN 
PDK2/PDK4 DOUBLE KNOCKOUT MICE 
1.  Overview 
The importance of pyruvate dehydrogenase kinases (PDK) 2 and 4 in regulation 
of the pyruvate dehydrogenase complex (PDC) was assessed in single and double 
knockout (DKO) mice.  PDK2 deficiency caused higher PDC activity and lower blood 
glucose levels in the fed but not the fasted state.  PDK4 deficiency caused similar effects 
but only after fasting.  Double deficiency intensified these effects in both the fed and 
fasted states.  PDK2 deficiency had no effect on glucose tolerance, whereas PDK4 
deficiency produced only a modest effect, but double deficiency caused a marked 
improvement and also induced lower insulin levels and increased insulin sensitivity.  In 
spite of these beneficial effects, the DKO mice were more sensitive than wild-type and 
single KO mice to long term fasting, succumbing to hypoglycemia, ketoacidosis, and 
hypothermia.  Stable isotope flux analyses indicated that hypoglycemia was due to a 
reduced rate of gluconeogenesis and that slightly more glucose was converted to ketone 
bodies in the DKO mice.  The findings establish that PDK2 is more important in the fed 
state, whereas PDK4 is more important in the fasted state.  These results indicate that 
survival during long periods of fasting depend upon  regulation of the PDC by both 
PDK2 and PDK4.  
 
2.  Introduction 
The pyruvate dehydrogenase complex (PDC) plays a pivotal role in controlling 
the concentrations of glucose in the fed and fasted state [46].  In the well fed state, PDC 
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is highly active, promoting glucose oxidation by generating acetyl-CoA which can be 
oxidized by the citric acid cycle or used for fatty acid and cholesterol synthesis.  In the 
fasted state, PDC is inactivated by phosphorylation by pyruvate dehydrogenase kinases 
(PDKs) to conserve three carbon compounds for the production of glucose [110].  
The four PDK isoenzymes responsible for phosphorylating the PDC are expressed 
in a tissue specific manner [44, 111, 112].  Among the four isoenzymes, PDK2 and 
PDK4 are most abundantly expressed in the heart [44, 50, 51], skeletal muscle [44, 52, 
53, 78], and liver [44, 49, 113-115] of fasted mice.  PDK2 is of interest because of its 
greater sensitivity to activation by acetyl-CoA and NADH and inhibition by pyruvate 
[116].  However, PDK4 has received greater attention because its expression is increased 
in many tissues by fasting and diabetes [49] and transcription of its gene is regulated by 
insulin, glucocorticoids, thyroid hormone, and fatty acids [58, 117].  Inactivation of the 
PDC by phosphorylation helps maintain euglycemia during fasting but contributes to 
hyperglycemia in type 2 diabetics.  The increase in PDK activity in diabetes begs the 
question of whether the PDKs should be considered as therapeutic targets for treatment of 
diabetes [118].  Support for this idea is provided by the finding that mice lacking PDK4 
are euglycemic in the fasted state and are more glucose tolerant than wild-type mice fed a 
high-fat diet [74, 80, 119]. 
In this study, PDK2 KO mice were produced to determine the importance of this 
isoform in glucose homeostasis.  In contrast to PDK4 KO mice, blood glucose levels 
were not lowered in the fasting state and glucose tolerance was not improved in mice 
lacking PDK2.  This raised the question of whether the presence of PDK4 compensates 
for the lack of PDK2 and vice versa.  To answer this question, PDK2/PDK4 DKO mice 
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were produced and characterized.  In contrast to the relatively mild phenotypes of the 
single KO mice, the DKO mice are unable to tolerate fasting for extended periods of 
time.  The findings show that survival during fasting depends upon inactivation of PDC 
by PDK2 and/or PDK4.  
 
 3.  Materials and Methods 
 3.1.  Animal protocol 
Mice were housed in an AALAC approved, pathogen-free barrier facility (12 h 
light/dark cycles with temperature maintained at 23 ± 2 °C) and ad libitum fed a standard 
rodent chow diet (Harlan; #7071).  Studies were conducted with approval of Institutional 
Animal Care and Use Committee of Indiana University School of Medicine.  Blood was 
collected from either a tail vein or the submandibular vein for the determination of 
metabolite levels.  To determine PDC activity and phosphorylation states, mice were 
anesthetized by injecting pentobarbital (60 mg/kg) intraperitoneally.  Blood was drawn 
from the inferior vena cava to measure metabolites.  Gastrocnemius muscle, liver, heart, 
kidney, testes, and brain were harvested as rapidly as possible followed by immediate 
freeze clamping with Wollenberger tongs at the temperature of liquid nitrogen, powdered 
in liquid nitrogen and stored at -85 °C for analysis.  Body temperature was determined 
with a rectal temperature probe (MicroTherma 2T; Braintree Scientific).  
 
3.2.  Generation of the PDK2/PDK4 DKO mice 
The procedures used to generate PDK4-/- (homozygous PDK4 KO mice) 
C57BL6J black mice [119, 120] and PDK2-/- (homozygous PDK2 KO mice) C57BL6J 
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black mice [121] were described previously.  PDK2 KO mice were crossed with PDK4 
KO mice to produce PDK2/PDK4 DKO mice.  Aged-matched wild type mice were 
produced from the C57BL6J black mice (The Jackson Laboratory, Bar Harbor, ME, 
U.S.A.) that were used to stabilize the genetic backgrounds of the PDK2 KO and PDK4 
KO mice.  
 
3.3.  Glucose and insulin tolerance tests 
Glucose tolerance tests were performed after mice had been fasted overnight (5 
p.m. to 9 a.m.).  Glucose (2 g/kg of body weight) was administered by intraperitoneal 
injection followed by measurement of glucose in tail blood by a glucometer (Accu-
Check; Roche) at 0, 15, 30, 60, and 120 min after injection.  Insulin tolerance tests were 
conducted after 6 h of fasting (8 a.m. to 2 p.m.).  Insulin (0.5 unit/kg of body weight; 
Humulin R, Eli Lilly) was administered by intraperitoneal injection.  Tail blood was 
taken for determination of glucose levels at 0, 15, 30, 60, and 120 min after injection. 
Mice were fasted overnight (5 p.m. to 9 a.m.) for the pyruvate tolerance test.  Pyruvate 
(1.5 g/kg of body weight) was delivered by intraperitoneal injection followed by 
collection of tail blood for measuring glucose at 0, 15, 30, 60, and 120 min.  Blood was 
collected from the jugular vein 30 min after pyruvate administration.  
 
3.4.  Measurement of metabolites concentrations in blood and liver 
Serum was deproteinized with 7% perchloric acid followed by neutralization with 
KOH and precipitation of KClO4.  Pyruvate [122], lactate [123], alanine [123], 
acetoacetate [124], β-hydroxybutyrate [124], and branched chain amino acids and α-
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ketoacids [125] were assayed by enzymatic methods.  Triacylglycerols were extracted 
with isopropyl alcohol and determined with an L-type TG H assay kit (Wako Chemicals, 
Richmond, VA). Free Fatty acids were assayed by the NEFA Half Micro Assay kit 
(Roche Diagnostics, Indianapolis, IN).  Blood pH, pCO2 and bicarbonate levels were 
measured with an I-STAT clinical analyzer with EC8+ cartridges (Heska Corporation, 
Loveland, CO).  Liver glycogen was measured by an enzymatic method [126]. 
 
3.5.  Metabolic flux analysis in the fasting condition 
Metabolic flux analysis was determined with stable-isotope-labeled glucose as 
described previously [127, 128].  Mice that had been fasted for 3 h (4:00 PM to 7:00 PM) 
were anesthetized with 5% isoflurane and surgically implanted subcutaneously with pre-
activated Alza miniosmotic pumps (model 2001D; 8 µL/h; Alzet Osmotic Pumps, Palo 
Alto, CA) containing 50 mg of [U-13C6]glucose (99.9% enriched; Isotech, Miamisburg, 
OH) dissolved in 200 µL of water.  Blood was collected from the mice between 10:00 
and 11:00 AM the next morning.   
 
3.6.  Mass isotopomer analysis using GC/MS 
Lactate and β-hydroxybutyrate were extracted from plasma with ethyl acetate. 
The residue obtained by drying the extract was treated with bis-trimethylsilyl 
trifluoroacetamide and trimethylchlorosilane (99:1, v/v) (Sulpelco Inc. Bellefonte, PA) 
before GC/MS analysis as described Des Rosiers et al. [129].  Analyses were performed 
on a Hewlett Packard Mass Selective Detector (model 5973A) connected to a Hewlett 
Packard Gas Chromatograph (model 5890) using chemical ionization with a ZB5 
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capillary column (30 meter × 250 µM (i.d.) × 0.25 µM film thickness (Phenomenex, 
Torrance, CA), methane as carrier gas with a flow rate of 1.0 ml/min, sample injector 
temperature 150 °C, and oven temperature held at 70 °C for 5 min and programmed at a 
ramp of 10 °C/min to 150 °C.  The clusters around m/z 219 and m/z 233 were monitored 
for isotopomer calculation.  For glucose analysis, the aqueous phase was deproteinized, 
deionized, dried, and treated with hydroxylamine hydrochloride and acetic anhydride to 
form aldonitrile pentaacetate derivatives for GC/MS analysis as described by Szafranek 
et al [130] with methane as carrier gas with a flow rate of 1.0 ml/min, sample injector 
temperature 250 °C, and oven temperature programmed from 210 to 250 °C at a ramp of 
10 °C/min.  The ion clusters around m/z 328 were monitored (m/z 327 to m/z 336).  
Mass isotopomer distribution was determined from the mass spectra as described 
previously [131, 132].  The method corrects for the contribution of derivatizing agent and 
natural 13C abundance to mass isotopomer distribution of the compound of interest and 
also for the presence of small amounts of m4 and m5 in the infused [U13C6]glucose.  Data 
for the mass isotopomers in glucose, lactate, or β-hydroxybutyrate are reported as molar 
fractions of m0, m1, m2, etc. according to the number of labeled carbons in the molecule 
[131, 132].  The enrichment of a certain 13C-labeled molecule is defined as its molar 
fraction mi, the fraction of molecules with i being the number of 13C substitutions.  The 
sum of all isotopomers of the molecules, Σmi for i = 0 to n (n = 3, 4 or 6 for lactate, β-
hydroxybutyrate, and glucose, respectively), is equal to 1 or 100%.  Substrate production 
or turnover rates were determined using the principle of tracer dilution.  At isotopic 
steady state, the hepatic glucose production (HGP) rate was determined from the equation 
[133]: 
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HGP (mg/min/kg) = (working pump rate)/m6 – working pump rate, where m6 = final 
substrate enrichment in glucose [127].    
The PDC produces [1,2-13C2]-acetyl-CoA (m2-acetyl-CoA) from [U13C6]glucose 
which can be incorporated into β-hydroxybutyrate with the formation of [1,2-13C2]- or 
[3,4-13C2]-β-hydroxybutyrate,  designated herein as m2-β hydroxybutyrate.  The amount 
of the ketone bodies in the blood produced from glucose was determined from the 
equation: ketone bodies produced from glucose (mmol/L) = [KB] x m2/(m6 x 2) where 
[KB] = sum of plasma concentrations of β-hydroxybutyrate and acetoacetate in mmol/L, 
m2 = 13C isotopomer enrichment in β-hydroxybutyrate, m6 = 13C isotopomer enrichment 
in glucose.  The factor 2 in the equation corrects for the two acetyl-CoA units required to 
produce β-hydroxybutyrate.  The sum of β-hydroxybutyrate and acetoacetate is used 
since both ketone bodies are assumed to be in equilibrium.  
 
3.7.  Measurement of enzyme activities 
For the determination of PDC activity, tissues were pulverized in liquid nitrogen 
and homogenized with a motor-driven Teflon homogenizer in 5 volumes (w/v) of 
extraction buffer containing 30 mM HEPES-KOH, pH 7.5, 3% (v/v) Triton X-100, 2 mM 
EDTA, 2% (v/v) rat serum, 5 mM dithiothreitol (DTT), 10 µM tosyl phenylalanyl 
chloromethyl ketone(TPCK), 10 µg/ml trypsin inhibitor, and 1 µM of leupeptin.  For the 
determination of actual PDC activity, i.e. the activity that exists in the intact tissue as a 
result of the phosphorylation state, an aliquot of tissue extract was mixed with an equal 
volume of re-suspension buffer containing 30 mM HEPES/KOH (pH 7.5), 1% Triton X-
100, 0.2 mM EDTA, 2% bovine serum, 1 µM leupeptin, 5 mM DTT, 20 mM 
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dichloroacetate, 100 mM KF.  For the determination of total PDC activity, i.e. the activity 
of the complex after complete dephosphorylation, an aliquot of tissue extract (25 µL) was 
mixed with an equal volume of an activation buffer (re-suspension buffer containing 40 
mM MgCl2, 1.5 mM CaCl2 and 1µg of recombinant pyruvate dehydrogenase phosphatase 
1 protein).  Complete activation of PDC by dephosphorylation was achieved by 
incubating of this mixture at 30 °C for 20 min.  Activity of the PDC was measured 
spectrophotometically in a 96 well plate reader (Spectra Max 190, Molecular Devices, 
Sunnyvale, CA) with a coupled assay based on the reaction catalyzed by arylamine 
acetyltransferase as described previously [134].  One unit of PDC activity corresponds to 
the acetylation of 1 µmol of p-(p-aminophenylazo)-benzenesulphonate per min at 30 °C. 
Phosphoenolpyruvate carboxykinase (PEPCK) activity was measured as 
described by Rajas et al. [135]; glucose-6-phosphatase activity as described by Foster et 
al. [136].  
 
3.8.  Western blot analysis 
Tissue powders (50 - 80 mg) prepared in liquid nitrogen were homogenized with 
8-10x (v/w) RIPA extraction buffer containing HaltTM protease inhibitor (1x) and 
phosphatase protease inhibitor cocktails (1x) (Thermo Scientific, Rockford, IL).  Protein 
was determined with a Bio-Rad Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA) 
using bovine serum albumin as standard.  Ten to 30 µg of protein were separated on 10% 
(w/v) SDS-PAGE [137] and transferred to nitrocellulose membranes (Bio-Rad 
Laboratories, Hercules, CA) by the semidry electroblotting method [53] and probed with 
antibodies against phospho-Ser293-PDHE1α (AP1062; EMD Chemicals), PDK2 (SC-
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100534, Santa Cruz Biotechnology) and PDK4 antiserum [119], HSP-60 (622562; 
Transduction Laboratories), and PDK1 (KAP-PK112; Stressgen).  Rabbit antiserum for 
PDK3 was generated by AbFRONTIER (Seoul, Korea) against the C-terminal 19 amino 
acids (rdaskykakqdkiksnrtf) that are unique to PDK3.  By Western blot analysis, the 
antiserum against this peptide detected a protein with the expected molecular weight of 
45 kDa in tissue extracts of organs (brain, kidney, and testes) known to express PDK3 
[44].  That this protein corresponded to PDK3 was confirmed by its absence in tissue 
extracts of brain, kidney, and testes harvested from PDK3 KO mice (kindly provided by 
Dr. Kirill M. Popov, University of Alabama at Birmingham).  Images of the Western 
blots were processed with a Gel DockTM XR+ Imaging System (Bio-Rad Laboratories, 
Hercules, CA).  
 
3.9.  Statistical analysis 
The statistical significance of differences between groups was determined by the 
Student’s t-test or one–way ANOVA when appropriate.  Values are presented as either 
means ± SD or means ± SEM with the indicated number of independent samples.  P 
values less than 0.05 were considered statistically significant. 
 
4.  RESULTS 
4.1.  Fed and fasting blood glucose levels in PDK2 KO, PDK4 KO, and PDK2/PDK4 
DKO mice 
PDK2 KO mice were generated to assess the importance of this kinase in glucose 
homeostasis during feeding and fasting.  PDK2 KO mice are viable and do not differ 
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from wild-type mice in growth and body composition when fed a standard rodent chow 
diet (Harlan; #7071) (data not shown).  Interestingly, relative to wild-type mice, blood 
glucose levels of PDK2 KO mice were reduced in the fed but not the fasted state (Table 
1).  In contrast, as we reported previously [119], PDK4 KO mice have lower blood 
glucose levels in the fasted but not the fed state (Table 1).  Not surprisingly, therefore, 
knocking out both PDK2 and PDK4 to produce DKO mice resulted in significantly lower 
blood glucose levels in both the fed and the fasted state, with the effect greater in the 
fasted than the fed state (Table 1).  
Genotype Fed Fasted
WT                                  174 ± 6                   94 ± 7
PDK2 KO                       149 ± 3*                  87 ± 7
PDK4 KO                       177 ± 11                 75 ± 2*
PDK2/PDK4 DKO          154 ± 4*                  61 ± 2* #
Blood Glucose   
mg/dl
 
Table 1.  Blood glucose levels in WT, PDK2 KO, PDK4 KO, and PDK2/PDK4 DKO 
mice in the fed and fasted states.  Mice were fasted overnight (12 hours).  * P < 0.05, 
compared to wild-type in the same nutritional state determined by Student’s t test.  # P < 
0.05, compared to PDK4 KO in the fasted state determined by Student’s t test.  All values 
are the mean ±  S.E.M. with  n = 4 mice per group except for n = 7 for wild-type. 
 
To further evaluate the effect of PDK deficiency on glucose homeostasis, glucose 
tolerance studies were conducted.  Previously we found glucose tolerance was mildly but 
significantly enhanced in PDK4 KO mice compared to wild-type mice (area under the 
curve reduced by 17 %, n=12 per group, P <0.01) [119].  In contrast, no difference in 
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glucose tolerance was found in direct comparison of PDK2 KO mice with wild-type mice 
(Figure 5A).  In spite of these findings, the tolerance of DKO mice to glucose was 
remarkably improved (area under the curve of 13413 + 1176 compared with 26592 + 
2749 mg/dL·min for wild-type mice; mean + SEM, n = 4 per group, P <0.05) (Figure 
5B). Insulin levels measured in blood collected 30 min after initiation of the glucose 
tolerance test were also lower in the DKO mice (1.0 + 0.2 for DKO mice compared to 2.5 
+ 0.9 ng/mL for wild-type mice; mean + SEM, n = 4 per group, P <0.05), consistent with 
greater insulin sensitivity in the DKO mice. 
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Figure 5.  Improved glucose tolerance and increased insulin sensitivity in 
PDK2/PDK4 DKO mice but not PDK2 KO mice.  (A) Glucose tolerance tests (GTTs) 
were performed on wild-type and PDK2 KO mice. WT, n 4; PDK2 KO, n = 4.  (B) GTTs 
were conducted with wild-type and PDK2/PDK4 DKO mice.  WT, n = 4; DKO, n = 4.  
(C) Food was removed from mice of the indicated genotypes for 24 h.  Blood glucose 
levels were determined at 0, 12, and 24 h after removal of food.  WT, n = 6 wild-type 
mice; PDK2 KO, n = 6; PDK4 KO, n = 6; DKO, n = 5.  (D) Insulin tolerance test was 
performed on wild-type and PDK2/PDK4 DKO mice.  WT, n = 6; DKO, n = 6.  All 
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values are the mean ± S.E.M.  * P < 0.05 relative to wild-type mice determined by 
Student’s t test. 
 
To determine the effect of prolonged fasting on blood glucose levels, mice of the 
four genotypes were concurrently fasted for 24 h.  Relative to wild-type mice 24 h-fasting 
significantly lowered blood glucose levels in the PDK4 KO and DKO mice but not in the 
PDK2 KO (Figure 5C).  Since glucose and insulin levels were lower in the DKO mice 
during the glucose tolerance test, an insulin tolerance test was conducted to assess insulin 
sensitivity.  Insulin had a greater effect on blood glucose levels in the DKO mice (Figure 
5D; area above the curve of 4800 + 294 compared to 3634 + 304 mg/dL·min for wild-
type mice; mean + SEM, n =6 per group, P <0.05), indicating greater insulin sensitivity 
than wild-type mice.  
 
4.2.  Effect of knocking out PDK2 and PDK4 on PDC activity state in the fed and 
fasted state 
Consistent with lower blood glucose levels in the fed state, the actual activity and 
activity state of PDC were increased in the liver and skeletal muscle of PDK2 KO and 
PDK2/PDK4 DKO mice (Table 2).  Likewise, consistent with the lack of an effect on 
blood glucose level in the fed state, the actual activity and activity state of PDC were not 
increased in the liver of PDK4 KO mice (Table 2).  However, the actual activity of the 
complex was significantly increased in the skeletal muscle.  
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Tissue                   Genotype                     Actual activity           Total activity       Activity State
Liver                     WT                             0.7 ± 0.1               2.47 ± 0.08             30 ± 4
PDK2 KO                   1.3 ± 0.1*              2.54 ± 0.08             51 ± 4*
PDK4 KO                  0.8 ± 0.2                2.3 ± 0.1                 32 ± 8
PDK2/PDK4 DKO    1.2 ± 0.1*               2.28 ± 0.06             56 ± 5*
Skeletal muscle  WT                             0.4 ± 0.1               3.7 ± 0.2                  9 ± 2              
PDK2 KO                 1.98 ± 0.04*           3.4 ± 0.3                  62 ± 4*
PDK4 KO                 2.0 ± 0.4*               4.2 ± 0.4                  49 ± 10*
PDK2/PDK4 DKO    4.0 ± 0.5*               5.7 ± 0.5*                76 ± 5* 
µmol/min/g wet weight tissue            % active
PDH Complex
 
Table 2.  PDC activity in liver and skeletal muscle of wild-type mice, PDK2 KO , 
PDK4 KO, and PDK2/PDK4 DKO mice in the fed state.  * P < 0.05 compared to 
wild-type determined by Student’s t test.  Values are the mean ± S.E.M. with n = 5 mice 
per group. 
 
Likewise, consistent with no effect on blood glucose levels in the fasted state, 
actual PDC activity in PDK2 KO mice did not differ from that of wild-type mice in the 
liver and skeletal muscle (Table 3).  In contrast, PDC actual activity was modestly 
enhanced in the liver and markedly increased in the skeletal muscle of fasted PDK4 KO 
mice (Table 3).  In spite of the absence of any effect of knocking out PDK2, the 
combined deficiency of PDK2 and PDK4 led to a three- and four-fold increase in PDC 
activity in the liver and skeletal muscle, respectively.  These findings suggest PDK2 is 
more important in the fed state whereas PDK4 is predominant in the fasted state.  This 
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agrees with the higher level of PDK2 expression in the fed state and the much greater 
induction of PDK4 in the fasted state [49]. 
Tissue                   Genotype                     Actual activity           Total activity            Activity State
Liver                   WT                              0.21 ± 0.01                2.31 ± 0.09           9.2 ± 0.8          
PDK2 KO                   0.17 ± 0.02                2.15 ± 0.04           8.1 ± 0.8
PDK4 KO                   0.28 ± 0.01*               2.28 ± 0.09          12.2 ± 0.8*
PDK2/PDK4 DKO      0.60 ± 0.09*               2.24 ± 0.10           27 ± 4*#
Skeletal muscle WT                              0.36 ± 0.01                2.56 ± 0.03            14.0 ± 0.4                         
PDK2 KO                   0.34 ± 0.02                2.56 ± 0.02            14.3 ± 0.8
PDK4 KO                   1.0 ± 0.1* 2.69 ± 0.02            39 ± 4*
PDK2/PDK4 DKO      1.85 ± 0.03*               2.73 ± 0.02            67 ± 1*#
µmol/min/g wet weight tissue               % active
PDH Complex
 
Table 3.  PDC activity in tissues of wild-type mice, PDK2 KO, PDK4 KO, and 
PDK2/PDK4 DKO mice in the fasted state.  Mice were fasted for 24 hours.  * P <  0.05 
compared to wild-type. # P < 0.05 compared to PDK4 KO determined by Student’s t test.  
Values are the mean ± S.E.M. with n = 4 mice per group. 
 
In this regard, it is noteworthy that double deficiency of PDK2 and PDK4 induced 
synergistic effects on PDC activity in both the liver and the muscle in the fasted state but 
not in the fed state (Tables 2 and 3).    
To confirm that increases in PDC activity are due to decreased phosphorylation of 
the E1α subunit of PDC, the relative amounts of phosphorylated protein for the primary 
phosphorylation site (serine293) of the E1α subunit of the PDC were determined by 
western blot analysis with a site-specific phosphoprotein antibody [138].  Since the 
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greatest increase in PDC activity was found in skeletal muscle of PDK2/PDK4 deficient 
mice, levels of phosphorylated E1αSer293 were determined in the skeletal muscle of 
wild-type, PDK2 KO, PDK4 KO, and DKO mice in the fed and fasted state (Figure 6).  
 
 
 
Figure 6.  Decreased phosphorylation of the PDH complex E1α subunit in the 
skeletal muscle of PDK KO mice.  (A) Representative immunoblots of the Ser293 
phosphorylated form of the PDH complex E1α subunit of skeletal muscle from wild-type, 
PDK2 KO, PDK4 KO, and PDK2/PDK4 DKO mice.  (B) Histograms constructed from 
data obtained by Western blot analysis.  Results are presented as mean ± S.D. with n = 3 
mice per group.  **P < 0.01; *** P < 0.001 relative to wild-type mice determined by 
one–way ANOVA. 
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As anticipated, levels of the phosphorylated E1α subunit of PDC relative to wild-
type mice were significantly reduced in PDK2 KO and PDK4 KO mice, and dramatically 
lowered in DKO mice, consistent with the actual activities of the PDC measured in the 
fed and fasted states.    
 
4.3.  Blood concentrations of gluconeogenic precursors and ketone bodies are 
greatly altered in PDK2/PDK4 DKO mice 
Knocking out the PDKs enhances PDC activity and thereby increases pyruvate 
oxidation, resulting in lower levels of pyruvate, lactate, and alanine, the principal three-
carbon substrates for gluconeogenesis [67, 119].  As predicated, serum levels of lactate, 
pyruvate, and alanine were significantly lowered in overnight fasted DKO mice (Table 
4).  
Measurement WT  DKO
Lactate 2.64 + 0.14             1.49 + 0.01*
Pyruvate 0.107 + 0.013         0.029 + 0.004*  
Alanine 0.21 + 0.02             0.11 + 0.01*
β-Hydroxybutyrate (HB) 0.92 + 0.13             3.85 + 0.61*
Acetoacetate (AcAc) 0.17 + 0.02             1.68 + 0.03*
Branched-chain amino acids 0.36 + 0.03             0.87 + 0.03
Branched-chain α- ketoacids 0.060 + 0.007         0.041 + 0.003*
Triacylglycerol 103 + 15                  117 + 32
[Lactate]/[Pyruvate]                25 + 2                      54 + 7*
[HB]/[AcAc]  5.5 + 0.6                  2.3 + 0.4*
 
Table 4.  Blood metabolic parameters of wild-type (WT) and DKO mice.  
Metabolites are given in units of mmol/L except triacylglycerol which is given in mg/dl. 
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* P < 0.05 for wild-type versus DKO mice. Values are the mean ± S.E.M. with n = 4 
mice per group. 
 
Since pyruvate is reduced more than lactate, the lactate to pyruvate ratio was 
greatly elevated in the DKO mice compared to wild-type mice.  Branched-chain amino 
acids levels were elevated but branched-chain α-ketoacids were reduced, consistent with 
the lowered availability of the pyruvate required to recycle glutamate back to α-
ketoglutarate for transamination of the branched-chain amino acids [119].  In contrast to 
the gluconeogenic precursors, β-hydroxybutyrate and acetoacetate were greatly increased 
in DKO mice (Table 4), in spite of there being no difference in serum levels of free fatty 
acids and triacylglycerol.  As a result of a greater increase in acetoacetate than in β-
hydroxybutyrate, and in striking contrast to the more reduced state of the lactate to 
pyruvate ratio, the hepatic β-hydroxybutyrate to acetoacetate ratio was decreased (1.3 ± 
0.2 in DKO mice compared to 1.68 ± 0.09 in wild-type mice, n = 6 mice per group, P < 
0.05), indicating a more oxidized mitochondrial matrix space in the DKO mice. 
 
4.4.  Fed and fasting liver glycogen levels in PDK2 KO, PDK4 KO, and PDK2/PDK4 
DKO mice  
In the fed state, liver glycogen levels of the DKO mice, but not the single KO 
mice, were significantly lower (17 %) than that of the wild type mice (Figure 7A).  After 
fasting for 24 h, liver glycogen remained higher in the wild-type mice than in the KO 
mice, higher in the PDK2 KO mice than in the other KO mice, and virtually depleted in 
the PDK4 KO and DKO mice (Figure 7B).  
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Figure 7.  Glycogen levels are reduced in PDK2/PDK4 DKO mice.  Liver glycogen 
levels in wild-type, PDK2 KO, PDK4 KO, and DKO mice in the fed state (A) and 24 hr 
fasted state (B).  All values are mean ± S.E.M. with n = 5 mice per group.  * P < 0.05; 
*** P < 0.001 relative to wild-type mice determined by Student’s t test.  
 
When considered in combination with the effect of fasting on blood glucose levels 
(Figure 8), these findings suggest liver glycogen was used more rapidly to maintain blood 
glucose levels in PDK deficient mice.  Retention of larger amounts of liver glycogen in 
the PDK2 KO mice than in the PDK4 and DKO mice is consistent with less effect of 
fasting on blood glucose levels.   
 
4.5.  Pyruvate tolerance and clearance is enhanced in DKO mice 
To determine whether exogenous pyruvate would eliminate the difference in 
fasting blood glucose levels between the wild-type and DKO mice, pyruvate was 
administered according to the standard pyruvate tolerance test.  The DKO mice showed a 
greater tolerance to exogenous pyruvate than wild-type mice (area under the curves 5725 
+ 30 and 8460 + 735 arbitrary units, respectively; n = 4 mice/group; P <0.02) (Figure 8).  
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Figure 8.  Pyruvate clearance is increased in PDK2/PDK4 DKO mice.  Blood glucose 
levels during pyruvate tolerance test with wild-type and PDK2/PDK4 DKO mice.  WT, n 
= 4; DKO, n = 4.  All values are mean ± S.E.M.  * P < 0.05; ** P < 0.01 relative to wild-
type mice determined by Student’s t test.  
 
Although blood glucose levels of the DKO mice were not restored to those of the 
wild-type, this can be explained by rapid clearance of pyruvate from the blood of DKO 
mice.  Whereas serum pyruvate concentrations measured 15 min after initiation of the test 
were high enough to maintain maximum rates of gluconeogenesis in both the wild-type 
(1.8 ± 0.3 mM)  and DKO mice  (0.7 ± 0.1 mM; mean ± SEM, n = 5 mice per group, P 
<0.05), the levels measured after 30 min were too low (0.039 ± 0.002 mM in DKO mice 
compared to 0.53 ± 0.04 mM for wild-type mice; mean ± SEM, n = 5 mice per group, P < 
0.001) and the lactate to pyruvate ratio was too high [139] in the DKO mice (106 ± 18 
compared to 18 ± 4 for wild-type mice; mean ± SEM, n = 5 mice per group, P < 0.01). 
The alanine concentration measured at 30 min in the DKO mice (0.041 ± 0.009 mM 
versus 0.32 ± 0.04 mM for wild-type mice; mean ± SEM, n = 5 mice per group, P < 0.01) 
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was also too low for maximum rates of glucose synthesis.  During the first 15 min of the 
test, glucose levels increased at comparable rates in wild type and DKO mice (3.7 ± 0.3 
and 3.4 ± 0.3 mg/dl/min, respectively; n = 4 mice/group; not significantly different). As 
expected from the measured concentrations of pyruvate and alanine, the rate of increase 
in glucose during the second 15 min of the test remained the same in the wild-type mice 
but fell off dramatically in the DKO mice (2.3 ± 0.5 mg/dl/min compared to 3.9 ± 0.3 
mg/dl/min for wild-type mice).  Therefore, under conditions of saturating concentrations 
of gluconeogenic substrates, i.e. the first 15 min of the test, no difference in rates of 
increase in glucose concentration were found between wild type and DKO mice, 
suggesting comparable enzymatic capacity for gluconeogenesis in DKO and wild-type 
mice.  
 
4.6.  Activities of key gluconeogenic enzymes are not reduced in the liver of DKO 
mice 
Consistent with the results of the pyruvate tolerance test, the activity of hepatic 
PEPCK was not different between the wild-type and DKO mice (1.50 ± 0.2 versus 1.25 ± 
0.15 µmol/min·g of wet weight for wild-type; mean + SEM, n = 5 mice per group; p = 
0.30) and the activity of glucose-6-phosphatase was greater rather than reduced in the 
DKO mice (1.54 + 0.13 versus 1.01 + 0.18 µmol/min·g of wet weight for wild-type mice, 
n = 5 per group, P <0.05), suggesting reduced enzymatic capacity for hepatic 
gluconeogenesis is not responsible for lower blood glucose levels in the DKO mice. 
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4.7.  Rate of glucose production is reduced in DKO mice 
Stable-isotope based metabolic flux measurements with [U-13C6]glucose revealed 
a 52% lower rate of glucose production in DKO mice relative to wild-type mice (Figure 
9). 
 
 
 
 
 
 
Figure 9.  Rate of glucose production is reduced in PDK2/PDK4 DKO mice.  Glucose 
production rate in wild-type and DKO after 18 h fast was determined using constant 
infusion of [U-13C6] glucose.  WT, n = 5; DKO, n = 6.  All values are mean ± S.E.M.   
**  P < 0.01 relative to wild-type mice determined by Student’s t test.  
 
Therefore, the lower blood glucose levels seen in the DKO mice can be explained 
at least in part by a lower rate of glucose production, which is consistent with the 
hypothesis that substrate supply limits the rate of gluconeogenesis in PDK deficient mice.  
 
4.8.  Contribution of acetyl-CoA produced by PDC to ketone body production in 
DKO mice 
In the fasted state, ketone bodies are primarily derived from acetyl-CoA produced 
by the oxidation of fatty acids in the liver.  Synthesis of ketone bodies from glucose and 
0
5
10
15
20
WT           DKO
**
G
lu
co
se
 P
ro
du
ct
io
n 
(m
g/
kg
/m
in
)
 
 46 
the three carbon compounds derived from glucose is largely prevented by inactivation of 
the PDC by phosphorylation.  Because the PDC remains partially active in the fasted 
state in DKO mice, glucose should contribute more carbon to the synthesis of ketone 
bodies in these mice.  This was examined by measuring the incorporation of carbon from 
[U-13C6]glucose into ketone bodies in wild-type and DKO mice.  As anticipated, greater 
β-hydroxybutyrate enrichment with two 13C carbons (m2-β-hydroxybutyrate) was found 
in the plasma of the DKO mice which combined with the greater concentration ketone 
bodies in the DKO mice established that more ketone bodies were produced from glucose 
in the DKO mice than in the wild-type mice (Figure 10A). 
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Figure 10.  The conversion of glucose into ketone bodies are increased in 
PDK2/PDK4 DKO mice.  (A) Plasma ketone bodies (β-hydroxybutyrate + acetoacetate) 
produced from glucose in wild-type and DKO mice after 18 h fast was determined using 
constant infusion of [U-13C6] glucose.  WT, n = 5; DKO, n = 6.  (B) Plasma NEFA levels 
were determined in male wild-type and PDK2/PDK4 DKO mice after overnight fast.  
WT, n = 4; DKO, n = 4.  *** P < 0.001 relative to wild-type mice determined by 
Student’s t test. 
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This finding is consistent with greater flux through the PDC with subsequent 
conversion of acetyl-CoA into ketone bodies.  However, the relative contribution of 
glucose carbon to the formation of ketone bodies was miniscule (<1% in both the wild 
type and DKO mice) relative to other carbon sources, which presumably were almost 
entirely fatty acids.  Since serum levels of free fatty acids were similar between DKO and 
wild-type mice (Figure 10B), greater availability of fatty acids for oxidation does not 
explain the increase in ketone bodies.   
 
4.9.  Fasting induces ketoacidosis and hypothermia in the DKO mice 
PDK4 KO mice tolerate fasting without evidence of metabolic decompensation 
[74, 80, 119].  Since preliminary studies suggested DKO mice are more sensitive to 
fasting, the metabolic effects of fasting for various periods of time were determined with 
wild-type, single KO, and DKO mice (Figure 11A & B).  Relative to wild-type mice, a 
modest but significant increase of β-hydroxybutyrate occurred after 12 h but not after 24 
and 36 h of fasting in PDK2 KO mice (Figure 11B).  In PDK4 KO mice, acetoacetate 
was significantly increased after 24 and 36 h of fasting and β-hydroxybutyrate after 36 h 
of fasting.  In the DKO mice, fasting induced much higher levels of both ketone bodies 
throughout the study than observed in the other genotypes.  Thirty-six h of fasting 
induced nearly a five-fold increase of acetoacetate in DKO mice compared to wild-type 
mice and two and a half-fold increase compared to PDK4 KO (Figure 11A).  In addition, 
the concentration of β-hydroxybutyrate was elevated about four-fold in the DKO mice 
compared to wild-type mice and two-fold compared to PDK4 KO mice (Figure 11B).  
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Figure 11.  Blood ketone bodies are increased in PDK2/PDK4 DKO mice.  (A) 
Plasma Acetoacetate and β-hydroxybutyrate.  (B) levels were determined in male wild-
type, PDK2 KO, PDK4 KO, and PDK2/PDK4 DKO mice after 0, 12, 24, and 36 h of 
food removal.  Values are mean ± S.E.M. with n = 5 in each group for each time point.  
* P < 0.05; ** P <0.01 relative to wild-type mice determined by Student’s t test. 
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Because ketosis can induce metabolic acidosis, blood pH of the DKO mice was 
determined.  Four hours of fasting significantly lowered blood pH in the DKO mice 
compared to wild-type mice (7.08 + 0.03 and 7.20 + 0.06, respectively; Figure 12A). 
After 24 h of fasting, blood pH of the DKO mice reached dangerously low levels (6.87 + 
0.07 and 7.22 + 0.03, respectively) due to severe ketoacidosis.  Unlike the response of the 
DKO mice, 36 h of fasting did not lower blood pH of PDK2 KO and PDK4 KO mice 
(Figure 12B).  
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Figure 12.  Fasting induces acidosis in PDK2/PDK4 DKO mice.  (A) Blood pH were 
determined in wild-type and PDK2/PDK4 DKO mice during fasting.  WT, n = 5; DKO, n 
= 5.  (B) Blood pH and bicarbonate (C) were determined in WT, PDK2, PDK4 KO, 
PDK2/PDK4 DKO mice during fasting.  Values are the mean ± S.E.M. with n = 4 per 
group.  * P < 0.05, ** P < 0.01, *** P < 0.001 relative to wild-type mice determined by 
Student’s t test. 
 
As expected, with the presence of acidosis, the concentration of bicarbonate was 
dramatically reduced in the DKO mice (9 + 2 mmol/L) compared to wild-type mice (20.7 
+ 0.7 mmol/L) (Figure 12C).  Furthermore, pCO2 was significantly reduced in DKO mice 
(25 +4 mm Hg ° versus 40 + 6 mm Hg °for wild-type mice; mean + SEM, n = 4 per 
group, P <0.05).  In addition to suffering from ketoacidosis, the DKO mice experienced 
hypothermia (27 ± 2 °C compared to 34.5 ± 0.7 °C in wild-type mice, n = 5 mice per 
group, P < 0.05) after 36 h of fasting, leading ultimately to death.  
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4.10.  Expression of PDK4 does not compensate for lack of PDK2 in PDK2 KO mice 
and vice versa 
PDK2 and PDK4 were measured by western-blot analysis to assess whether 
altered expression of these proteins compensates for the lack of PDK2 and PDK4 in the 
corresponding KO mice (Figure 13).  
_________ _________   __________ _________   _________  _________WT              PDK4 KO                   WT                 PDK2 KO                  WT                   DKO
__________________    ___________________    ___________________PDK2                                              PDK4          PDK1 
(A)
(B)
(C)
 
Figure 13.  Deficiency of PDK2, PDK4, and both PDK2 and PDK4 does not increase 
expression of other PDK isoforms in the heart, liver, and skeletal muscle.  Protein 
levels of PDK2, PDK4, and PDK1 were determined by western blot analysis in the heart 
(A), liver (B), and skeletal muscle (C) of PDK4 KO mice, PDK2 KO mice, and 
PDK2/PDK4 DKO mice. 
 
Protein levels of PDK2 were not changed in the tissues of the PDK4 KO mice 
compared to wild-type mice.  Protein levels of PDK4 were likewise similar in heart, liver, 
and skeletal muscle of PDK2 KO mice and wild-type mice.  These findings suggest that 
in the fasted state expression of PDK2 does not compensate for the lack of PDK4 and 
expression of PDK4 does not compensate for the lack of PDK2.  
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4.11.  Expression of PDK1 and PDK3 does not compensate for the lack of PDK2 and 
PDK4 in the DKO mice 
Levels of PDK1 protein were similar in the liver and skeletal muscle of wild-type 
mice, PDK2 KO mice and PDK4 KO mice (data not shown) suggesting that PDK1 does 
not compensate for the loss of PDK2 or PDK4.  Furthermore, the amounts of PDK1 
expressed in the liver and skeletal muscle were similar for wild-type and DKO mice but 
slightly reduced in the heart of DKO mice (Figure 13).  Therefore, the expression of 
PDK1 does not compensate for the lack of PDK2 and PDK4 in the DKO mice.  PDK3 
protein could not be detected in the liver, skeletal muscle, and heart of wild-type and 
DKO mice with an antibody that readily detects this protein in brain, testes, and kidney 
(data not shown).      
 
5. Discussion 
This study shows PDK2 deficiency lowers blood glucose in the fed state without a 
large increase in ketone bodies.  PDK4 deficiency lowers blood glucose in the fasted 
state, with a significant increase in ketone bodies, and a combined PDK2 and PDK4 
deficiency lowers blood glucose in both the fed and fasted states, with an increase in 
ketone bodies that culminates in metabolic acidosis and decompensation.  
The finding that PDK2 was effective in the fed state but not the fasted state was 
unexpected but can be rationalized on the basis of the expression pattern and regulatory 
properties of PDK2 relative to the other PDKs.  PDK2 is constitutively expressed in 
tissues in the fed and fasted state [49, 68], its activity is more sensitive than the other 
PDKs to modulation by pyruvate, NADH, and acetyl-CoA [116, 140], and its expression 
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level is only modestly increased by fasting in the liver and kidney of rats [53] and by 
diabetes in Otsuka Long-Evans Tokushima Fatty rats [68], and in type 2 diabetes in 
humans [141].  Because these observations seemed to suggest an important role for 
PDK2 in regulation of glucose metabolism during fasting and in diabetes, we were 
surprised to find blood glucose is maintained at normal fasting levels in PDK2 knockout 
mice.  Consistent with this observation, knocking out PDK2 had no effect upon the 
phosphorylation and activity state of the PDC in the fasted state in either the liver or the 
skeletal muscle.  Because PDK2 deficiency does not alter PDC activity, the rate of 
pyruvate oxidation is not increased and therefore the supply of 3 carbon compounds for 
hepatic and renal glucose production is not affected in these mice.  Since gluconeogenesis 
was not limited by substrate supply, glucose levels were not affected.   
In wild-type mice, the PDC is normally less phosphorylated and more active in 
the fed state than in the fasted state.  Nevertheless, a large portion of the complex remains 
phosphorylated and catalytically inactive in the fed state.  Therefore, a considerable 
reserve of PDC activity exists in the fed state that can be called into play by 
dephosphorylation when needed.  This study suggests PDK2 plays an important role in 
phosphorylating PDC, and therefore maintaining this reserve of PDC activity in the fed 
state.  Rendering mice deficient in PDK2 reduces this reserve, resulting in greater PDC 
activity and therefore a greater rate of glucose disposal and lower glucose levels in the 
fed state.  Because gluconeogenesis is inhibited in the fed state, lower blood glucose 
levels are not the result of reduced rate of glucose production but rather increased glucose 
disposal. 
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PDK4 has received most of the attention in studies on physiological regulation of 
the PDC because its expression is more sensitive to the metabolic stress of fasting and 
diabetes [53].  The expression of PDK4 is remarkably sensitive to stimulation by 
glucocorticoids and PPARα and δ ligands and to inhibition by insulin [58, 142, 143], 
consistent with an important role for PDK4 in setting the phosphorylation and activity 
state of PDC in fasting and diabetes.  In addition, fasting blood glucose levels are 
significantly reduced in PDK4 KO mice relative to that of corresponding control mice 
[74, 119].  In the present study, the phosphorylation state of PDC was found to be 
reduced in PDK4 KO mice, consistent with the increase in PDC activity state reported 
previously [17].  Lactate, pyruvate, and alanine levels are therefore reduced in PDK4 
mice, resulting in lower blood glucose levels for want of 3 carbon compounds for 
gluconeogenesis.  In the fed state PDK4 deficiency has no effect on blood glucose 
because PDK4 is not expressed at high enough levels to impact the activity state of PDC. 
PDK4 is effective in the fasted state because of the higher level of its expression and 
therefore its greater importance in regulation of PDC.   
Double deficiency of PDK2 and PDK4 greatly increased PDC activity and 
reduced blood glucose levels in both the fed and the fasted state.  Whereas a greater rate 
of glucose oxidation can explain the reduced level of blood glucose in the fed state, the 
reduced concentrations of pyruvate, alanine, and lactate suggest that a decreased supply 
of substrates needed for gluconeogenesis is the mechanism by which double deficiency of 
PDK2 and PDK4 reduces blood glucose levels in the fasted state.  Consistent with this 
hypothesis, metabolic flux analysis with [U-13C6] glucose indicated DKO mice 
synthesized glucose at a lower rate than wild-type mice.  Furthermore, no difference in 
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phosphoenolpyruvate carboxykinase (PEPCK) activity, which limits the rate of 
gluconeogenesis under some conditions, was found between DKO and wild-type mice. 
Furthermore, glucose-6-phosphatase was slightly elevated rather than reduced in DKO 
mice.  These findings suggest altered enzymatic capacity for gluconeogenesis is not 
responsible for lower blood glucose levels in DKO mice.  It is more likely, therefore, that 
reduced substrate supply for gluconeogenesis limits the rate of hepatic/renal glucose 
production in the DKO mice.  These data support findings with the PDK inhibitor 
dichloroacetate, [67, 69, 144], which lowers blood glucose levels by reducing the rate of 
gluconeogenesis by decreasing the blood levels of pyruvate, lactate, and alanine [67].   
Even though PDK deficiency results in lower blood glucose levels [119] and, 
therefore may serve as a therapeutic target for type 2 diabetes [118], lack of control of 
PDC activity by PDK2 and PDK4 greatly increases blood ketone body levels.  Overnight 
fasting of DKO mice caused a four-fold increase in β-hydroxybutyrate and ten-fold 
increase in acetoacetate.  Ketone bodies were not significantly affected in PDK2 KO 
mice compared to wild-type mice, and although elevated in the PDK4 KO mice, ketone 
body levels in these mice remained much lower than in the DKO mice.  Furthermore, 
acidosis was induced by the ketosis in DKO mice, resulting in fatally low blood pH after 
24 h of food deprivation.  Although PDK4 KO mice have elevated ketone bodies, these 
animals maintain blood pH levels in the normal range.  Therefore, PDK2 and PDK4 are 
essential for preventing ketoacidosis during fasting.  At least in part, this is because 
inhibition of the PDC by PDK2 and PDK4 prevents competition between pyruvate and 
ketone body oxidation in peripheral tissues [119].  Studies with PDK inhibitor DCA 
showed that increased glucose oxidation inhibits ketone body oxidation [67].  In addition, 
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inhibition of the PDC by PDK2 and PDK4 limits the conversion of the carbon of glucose 
and gluconeogenic precursors to ketone bodies.  Normally the PDC is inactive in the 
fasted state and acetyl-CoA, which is derived primarily from fatty acid oxidation, 
produces ketone bodies.  The greater enrichment of ketone bodies with m2 β-
hydroxybuytrate originating from [U-13C6]g lucose shows that knocking out PDK2 and 
PDK4 increases PDC activity, resulting in production of acetyl-CoA from pyruvate that 
can be used to synthesize ketone bodies, although in amounts insignificant relative to the 
ketone bodies formed from fatty acids.    
In contrast to the single KO mice, PDC activity is greatly increased in the liver 
and skeletal muscle of the PDK2/PDK4 DKO mice, resulting in mice that cannot survive 
an extended period of fasting because of hypoglycemia, ketoacidosis, and hypothermia. 
Since PDK2 KO and PDK4 KO mice have mild phenotypes compared to the DKO mice, 
we predicted that compensation by increased expression of the other PDKs might protect 
single KO mice from deleterious effects experienced by the DKO mice.  However, the 
expression of PDK2 does not compensate for the lack of PDK4 and the expression of 
PDK4 does not compensate for the lack of PDK2.  Therefore, the modest phenotype of 
the PDK2 KO and PDK4 KO relative to the DKO is not due to up regulation of the 
expression of PDK2 or PDK4.  Instead, the intrinsic activity of PDK4 and its sensitivity 
to stimulation by acetyl-CoA and NADH [116] may be sufficient to cover for the absence 
of PDK2.  Likewise, PDK2 may be able to cover partially but less effectively for the 
absence of PDK4 in PDK4 KO mice.  The phenotype of the DKO mice is much more 
severe because these compensatory effects are not possible, and also because PDK1 and 
PDK3 are unable to cover for the absence of PDK2 and PDK4.   
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This study documents a precaution relative to the potential use of PDK inhibitors 
for the treatment of diabetes.  Double deficiency of PDK2 and PDK4 renders mice 
sensitive to hypoglycemia, ketoacidosis, and hypothermia during fasting.  Previous 
studies showed that knocking out PDK4 inhibits fatty acid oxidation in isolated 
diaphragms, suggesting that PDK deficiency impairs peripherial fatty acid oxidation, 
resulting in hypothermia  in DKO mice [119].  From these findings it is clear that 
compounds that totally inhibit PDK2 and 4 would have deleterious effects.  Finally, it is 
noted that children with idiopathic ketoacidotic hypoglycemia suffer fasting-induced 
hypoglycemia and ketoacidema as a result of reduced levels of the gluconeogenic 
precursors [145].  Since similar effects are observed in PDK2/PDK4 DKO mice, PDK 
deficiency is a potential cause and these mice might serve as an animal model for this 
disorder. 
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CHAPTER II: PDK2/PDK4 DOUBLE KNOCKOUT MICE FED A HIGH FAT 
DIET REMAIN EUGYLEMIC BUT ARE PRONE TO KETOACIDOSIS 
1.  Overview 
The pyruvate dehydrogenase kinases (PDKs) inactivate the pyruvate 
dehydrogenase complex (PDC) to conserve substrates for gluconeogenesis.  Since 
excessive gluconeogenesis contributes to hyperglycemia in type 2 diabetics, decreasing 
the supply of glucoeneogenic substrates by inhibiting the PDKs is an attractive 
mechanism for lowering excessive hepatic glucose production.  To investigate whether 
PDK inhibition prevents hyperglycemia in a diet induced diabetic animal model, 
PDK2/PDK4 double knockout (DKO) mice were fed a high saturated fat diet for 30 
weeks.  The DKO mice remained euglycemic, accumulated less body fat, and were more 
glucose tolerant than wild type mice.  Stable isotope flux analysis indicated that 
euglycemia was due to a reduced rate of gluconeogenesis.  PDK deficiency resulted in 
greater PDC activity which limited the availability of pyruvate for oxaloacetate synthesis. 
Since oxaloacetate is essential for TCA cycle activity, suppression of oxaloacetate in 
DKO mice limited acetyl-CoA from entering the TCA cycle.  Subsequently, ketone body 
and fatty acid oxidation was suppressed, provoking fasting induced ketoacidosis and 
hypothermia in DKO mice.  When fed a very high fat, low carbohydrate diet, DKO mice 
also exhibited hypothermia, ketoacidosis, and hypoglycemia.  These effects of PDK 
deficiency plus elevated lactate to pyruvate ratios, reduced β-hydroxybutyrate to 
acetoacetate ratios, and increased blood citrulline levels are similar to the metabolic 
imbalance induced by suppression of oxaloacetate in pyruvate carboxylase deficiency in 
humans. 
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2.  Introduction 
The pyruvate dehydrogenase complex (PDC) links glycolysis to the citric acid 
cycle by transforming pyruvate to acetyl-CoA [46].  The PDC is subject to 
phosphorylation by pyruvate dehydrogenase kinases (PDKs).  Under fasting conditions, 
the expression of PDK2 and PDK4 is elevated, which in turn phosphorylate and 
inactivate the PDC.  As a consequence of an inactive PDC, the conversion of pyruvate to 
acetyl-CoA is reduced, resulting in conservation of pyruvate needed for gluconeogenesis.  
Inactivating PDC benefits the starved state by conserving gluconeogenic substrates for 
hepatic glucose production to maintain blood glucose levels [110].  Since excessive 
hepatic glucose production accounts for a significant proportion of the hyperglycemia in 
type 2 diabetes, prevention of the inactivation of the PDC should lower blood glucose in 
the diabetic state by inhibiting gluconeogenesis.  A significant up regulation of PDK2 and 
PDK4 occurs in type 2 diabetic humans [77], in genetic type 2 diabetic animal models 
[68], in animals fed a high fat diet [78], and in humans consuming high fat diet [79].  
Therefore, we placed PDK2/PDK4 double knockout mice on a high saturated fat diet to 
investigate whether PDK inhibition protects against hyperglycemia in a diet-induced 
diabetic animal model.  On the high fat diet, DKO mice maintained normal blood glucose 
levels and were protected from adiposity and fasting induced hepatic steatosis compared 
to wild-type mice.  However, similar to DKO mice fed the chow diet [146], these mice 
suffered from ketoacidosis and hypothermia under fasting conditions.  This raised the 
question whether elevated levels of blood ketone bodies are caused by increased 
ketogenesis or ketolysis and whether hypothermia is a consequence of reduced fatty acid 
oxidation.  To answer these questions, rates of ketogenesis, ketolysis, and fatty acid 
oxidation were determined.  DKO mice were unable to utilize ketone bodies and fatty 
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acids, two essential substrates for energy production in fasted state.  Without these 
substrates, survival of DKO mice in the fasted state was jeopardized.  
 
3.  Materials and Experimental Procedures 
3.1.  Animals  
Mice were housed in an AALAC approved, pathogen-free barrier facility (12 h 
light/dark cycles) with temperature maintained at (23 ± 2 °C).  The procedure to generate 
homozygous PDK2/PDK4 double knockout (DKO) mice and C57BL6J mice were 
described previously [146].  At 6 weeks of age, groups of 24 male wild-type and 24 male 
DKO mice were housed with three mice per cage and fed a high fat diet (D12330; 
Research Diets) that by calories was 58% fat, 16.4% protein, and 25.5% carbohydrate.  
According to the supplier, the fat composition of the high saturated fat diet was 93.3% 
saturated fat, 2.4% monounsaturated fat, and 4.3% polyunsaturated fat.  Body weights of 
the mice were determined once a week.  The experiment was terminated after 30 weeks 
of feeding. Food was removed from half of the mice in each group in the evening 
(between 7 and 8 p.m.).  The next morning (between 7 a.m. and 8 a.m.) mice were 
sacrificed by cervical dislocation and tissues were harvested and immediately freeze-
clamped with Wollenberger tongs at the temperature of liquid nitrogen, and later 
powdered under liquid nitrogen with a mortar and pestle, and stored at -85°C for analysis.  
Small pieces of tissue were also collected without freezing for histological analysis.  
To determine the response to a ketogenic diet, mice were fed a low carbohydrate-
high fat diet (TD963555; Harlan Tekland Premier Laboratory Diets) that by calories was 
90.5% fat, 9.5% protein, and 0.4% carbohydrate.  At eight weeks of age, groups of 12 
wild-type and 12 DKO mice were fed either the high saturated fat diet (D12492) or 
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ketogenic diet (TD963555).  After 2 days on the diets, mice were killed in the morning 
(between 9 a.m. and 10 a.m.) by cervical dislocation followed by collection of blood and 
harvesting of tissues.  Body temperature was measured by a rectal temperature probe 
(MicroTherma 2T, Braintree Scientific Inc, Braintree, MA).   
 
3.2.  Exercise Protocol. 
To determine the response to exercise, the mice were trained for 4 days (3 
min/day) on a treadmill designed for mice (Exer6M, Columbus Instruments).  On the first 
day, the treadmill incline was set to 5° with an intial speed of 8 m/min which was 
increased by 1 m/min during the training session.  Each day during the training session, 
the incline was increased by 5° and the initial speed to 10, 11, and 12 m/min.  For the 
exercise performance test, mice were run on a treadmill (20° incline with a starting speed 
of 12 min/min) followed by gradual increase in speed by 1 m/min at 2, 5, 10, 20, 30, 40, 
and 60 min after initiation of the exercise.  Mice that stepped off the belt experienced a 
mild electrical stimulus (16-28 V).  Exhaustion was defined as the point at which the 
mice were unable to continue running.  
 
3.3.  Measurement of body fat 
Percentage body fat of the mice was determined by DEXA (dual-energy X-ray 
absorptiometry) with a Lunar PIXImus Mouse Densitometer (GE Healthcare).  Mice 
were anaesthetized with 1.5% isoflurane [2-chloro-2-(difluoromethoxy)-1,1,1-
trifluoroethane] during the measurement.  
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3.4.  Glucose and insulin tolerance tests 
At 26th week of feeding, glucose tolerance tests were performed with mice that 
were fasted for twelve hours (7 p.m. to 7 a.m.).  Glucose (1 g/kg of body weight) was 
administered by intraperitoneal injection followed by measurements of glucose in tail 
blood with a glucometer (Lifescan) at 0, 15, 30, and 60, and 120 min after injection.  At 
the end of the 27rd week of feeding, insulin tolerance tests were conducted after 6 h of 
fasting (8 a.m. to 2 p.m.).  Insulin (1 unit/kg of body weight; Humulin R, Eli Lilly) was 
administered by intraperitoneal injection.  Tail blood was taken for determination of 
glucose levels at 0, 15, 30, 60, and 120 min after injection.  
 
3.5.  Measurements of metabolite concentrations in blood, skeletal muscle, and liver 
Serum and tissue extracts were deproteinized with perchloric acid followed by 
neutralization with KOH and precipitation of KCIO4.  Pyruvate [122], lactate [123], 
alanine [123, 147], acetoacetate [124], β-hydroxybutyrate [124], oxaloacetate [148, 149], 
malate [149], citrate [150], α-ketoglutarate [149] were assayed by enzymatic methods. 
Triacylglycerols were extracted with isopropyl alcohol and determined with an L-type 
TG H assay kit (Wako Chemicals, Richmond, VA).  Free Fatty acids were assayed by a 
NEFA Half Micro Assay kit (Roche Diagnostics, Indianapolis, IN).  Free Fatty acids 
were assayed by a NEFA Half Micro Assay kit (Roche Diagnostics, Indianapolis, IN).  
Blood pH and bicarbonate levels were measured with an I-STAT clinical analyzer with 
cartridge EC8+ cartridges (Heska Corporation, Loveland, CO).   
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3.6.  Glucose and ketone body utilization by isolated diaphragms 
Diaphragms were removed from 16 h starved mice and pre-incubated as 
previously described by Jeoung et al. [119].  After pre-incubations, diaphragms were 
removed from the flasks, blotted, and transferred into to new flasks containing 1.5 mL of 
Krebs-Henseleit bicarbonate buffer supplemented with 5 mM glucose containing 25 
µCi/mmol [U-14C]glucose and 1 mU/mL Insulin (Eli Lilly, Indianapolis, IN).  Flask were 
flushed with 95 % O2 / 5 % CO2, sealed with rubber serum caps which were fitted with 
hanging center wells (Kontes, Vineland, NJ) and incubated for 1 h shaking at 37 °C. 
Reactions were determined by the injection of 0.250 mL of phenethylamine/methanol 
(1:1, v/v) into the center wells and 0.1 mL of 60% (w/v) HClO4 into the contents of the 
flasks.  The rate of β-hydroxybutyrate was determined from the production of 14CO2.  To 
measure β-hydroxybutrate oxidation, diaphragms obtained from 16 h fasted mice were 
rinsed, weighted, and preincubated for 30 min as previously described [119].  
Diaphragms were removed from the flasks, blotted, weighed, and transferred into new 
flasks containing 1.5 mL of Krebs-Henseleit bicarbonate buffer (pH 7.4), 5 mM glucose, 
1mU/mL insulin, 50 µCi/mmol [3-14C]β-hydroxybutyrate.  14CO2 was collected after 1 h 
incubation as described above.  
 
3.7.  Metabolic flux analysis in the fasting condition 
Metabolic flux analysis was determined with stable-isotope-labeled glucose as 
described previously [127, 128].  Mice that had been fasted for 3 h (4:00 PM to 7:00 PM) 
were anesthetized with 5% isoflurane and surgically implanted subcutaneously with pre-
activated Alzet miniosmotic pumps (model 2001D; 8 µL/h; Alzet Osmotic Pumps) 
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containing 50 mg of [U-13C6]glucose or 50 mg of [U-13C4]β-hydroxybuytrate (99.9% 
enriched; Isotech, Miamisburg, OH) dissolved in 200 µL of water.  Blood was collected 
from the mice between 10:00 and 11:00 AM the next morning.  Mass isotopomer analysis 
using GC/MS was determined as described previously [146].  Substrate production or 
turnover rates were determined using the principle of tracer dilution.  At isotopic steady 
state, the hepatic glucose production (HGP) rate was determined using the following 
equation [133]: 
HGP (mg/min/kg) = (working pump rate)/m6 – working pump rate, where m6 = final 
isotope substrate enrichment in glucose [127].   Similarly, β-hydroxybutyrate production 
rate (mg/min/kg) can be calculated using the following equation: 
β-HBP = (working pump rate)/m4 – working pump rate, where m4 = final isotope 
enrichment in β-hydroxybutyrate. 
 
3.8.  Oxygen consumption, energy expenditure, and fatty acid oxidation 
Measurements of oxygen consumption and carbon dioxide production were 
performed using a TSE indirect calorimetry system (Lab Master, TSE systems, Midland, 
MI).  Mice were individually housed in the chamber for 48 h with lights on from 7 a.m. 
to 7 p.m. in an ambient temperature of 22-24 °C.  Food was removed during the dark 
cycle (7 p.m. to 7 a.m. the next following morning) for 24 h.  The TSE systems measured 
carbon dioxide produced and oxygen consumed over a 1-min period six times per hour. 
These values were averaged to determine the rate of carbon dioxide produced (VCO2) 
and oxygen consumed (VO2) in mL/h.  Energy expenditure (EE), respiratory quotient 
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(RQ), and fatty acid oxidation (FA) were calculated using the following equation [151, 
152]: 
RER = VCO2/VO2 
EE (kcal/h) = [3.815 + 1.232 X RER) x VO2] / 1000 
FA oxidation (kcal/h) = EE X (1 – RER/0.3) 
 
3.9.  Determination of nucleotides in the liver and skeletal muscle 
Analyses were performed with a Shimadzu Prominence HPLC System equipped 
with the LC20 AD Solvent Delivery System and SPD-M20A Photodiode Array Detector, 
using absorbance at 259 nm for quantification.  Nucleotides were separated using a 
Phenomenex Gemini reverse phase column (250 x 4.6 mm, 5 µm particle size) and a 
Phenomenex Security Guard C18 precolumn (4 x 3.0 mm), with gradient elution.  Mobile 
phase A was prepared by adjusting the pH of 0.1 M KH2PO4 to 6.0 with 0.1 M K2HPO4.  
Mobile phase B consisted of mobile phase A and methanol (80:20).  Extracts were 
diluted (20:60) with mobile phase B and 10 µL was injected onto the HPLC column for 
analysis.  Linear gradients of mobile phase, flow and temperature were utilized as 
follows:  0-7.5 min, 0-1 % B; 7.5-10 min, 1-3 % B; 10-17 min, 3-10 % B; 17-28 min, 10-
100% B.  The initial flow rate of 0.5 mL/min was held constant for 10 min.  From 10-12 
min the flow was increased from 0.5 to 1.0 mL/min and held constant until the end of the 
run.  From 0-6 min the temperature was increased from 25 to 29 ºC, from 6-15 min the 
temperature was returned to 25 ºC.  Peaks of interest eluted within 27 min, and the 
system was equilibrated for an additional 15 min prior to the next injection. The 
concentration of the highest AMP standard solution was determined using absorbance at 
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259 nm with a Cary 50 Bio UV-Visible Spectrophotometer (Varian) and the molar 
absorption coefficient of AMP (15,400 M-1 cm-1 at 259 nm).  Peak areas of the samples 
were quantified relative to an AMP standard curve then multiplied by the ratio of the 
molar absorption coefficient of AMP to that of the compound of interest.  The molar 
absorption coefficient of ADP and ATP is the same as AMP.  The molar absorption 
coefficient of NAD and NADP is 18,000 M-1 cm-1, and that of GMP, GDP and GTP was 
determined to be 12,300 M-1 cm-1 at 259 nm.    
 
3.10.  Histochemistry of the livers 
Histological examinations and preparation of H&E staining of the liver were 
performed by the Immunohistochemistry Laboratory of Indiana University School of 
Medicine (Indianapolis, IN, U.S.A.). 
 
3.11.  Statistical analysis   
The statistical significance of differences between groups was determined with 
the Student’s t-test.  All values are presented as means ± SEM with the indicated number 
of independent samples.  P values less than 0.05 were considered statistically significant. 
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4.  Results 
4.1.  Body weight gain, body fat and liver fat accumulation are attenuated in DKO 
mice fed a HSF diet.  
Wild-type and DKO mice were fed a high saturated fat (HSF) diet for 30 weeks. 
During the first eleven weeks, DKO mice and wild-type mice experienced the same 
weight gain (Figure 14). 
Figure 14.  Body weight gain is attenuated in DKO mice fed a HSF diet for 30 
weeks.  Wild-type and DKO mice were fed a high saturated fat (HSF) diet for 30 weeks.  
The body weights of the mice were measured at the beginning of every week from the 
beginning of the feeding period.  WT, n = 24; DKO, n = 24.  All values are the mean ± 
S.E.M. * P < 0.05 relative to wild-type mice determined by Student’s t test.  
 
However, by the 14th week DKO mice weighed significantly less than wild-type 
mice, a trend that continued through the 25th week.  After that, no difference in body 
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weight was apparent between the two groups.  In spite of this, the body fat percent 
measured by DEXA was significantly less in the DKO mice (32 ± 2%) compared to the 
wild-type mice (39 ± 1%; mean ± SEM, n = 6 mice/group, P < 0.05).  In agreement with 
these findings, relative percentage of epididiymal fat pad to body weight was less in the 
DKO mice (4.9 ± 0.3 % ) compared to wild-type mice (6.0 ± 0.1 %; mean ± SEM; n = 8 
mice/group, P < 0.05).  Although DKO mice accumulated less body fat, fat content of the 
livers of fed DKO mice was similar to that of fed wild-type mice (Figure 15A).  In the 
fasted state, however, the fat content of the liver of DKO mice was less than that of wild-
type mice (Figure 15B).  As observed previously with PDK4 KO mice [80], fat 
accumulated in microvesicles in the DKO mice rather than macrovesicles which is 
characteristic of HFD fed wild-type mice (Figure 15B).  
WT
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Figure 15.  Fasting induced hepatic steatosis is reduced in DKO mice fed a HSF diet. 
Microscopic photographs demonstrating histological appearance of livers of wild-type 
and DKO mice fed the high HSF diet for 30 weeks.  (A) Livers were obtained from wild-
type and DKO mice in fed state.  (B) Livers were obtained from wild-type and DKO 
mice after overnight fast.  Tissue sections were stained with hematoxylin and eosin 
(H&E) stain.  The material stained white corresponds to fat droplets.  (C) Triacylglycerol 
(TG) was determined in the fed and fasted livers of wild-type and DKO mice. WT, n = 
12; DKO, n = 12.  All values are the mean ± S.E.M.  * P < 0.05 relative to wild-type mice 
determined by Student’s t test.  
 
In agreement with the histology data, liver triacylgycerol content was similar 
between the groups of mice in the fed state (Figure 15C).  In the starved state, however, 
liver triacylglycerol levels were significantly reduced in DKO mice relative to wild-type 
mice (Figure 15C), confirming the histological evidence that fasting induced less hepatic 
steatosis in DKO mice relative to wild-type mice.  Although DKO mice accumulates less 
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fat in the liver as well as the whole body, DKO mice consumed similar amounts of food 
as wild-type mice.  
 
4.2.  Hyperglycemia is attenuated in DKO mice fed the HSD 
 In the fed state, DKO maintained similar blood glucose levels as wild-type mice 
(198 ± 13 mg/dL for wild-type mice and 186 ± 19 mg/dL for DKO  mice; n = 8 
mice/group, P > 0.05).  However, in the fasted state, wild-type mice remained 
hyperglycemic (147 + 11 mg/dL; n = 10) whereas the DKO mice lowered their blood 
glucose into the normal range of fasting blood glucose concentrations (87 + 7 mg/dL; n = 
10; P < 0.001). 
 
4.3.  DKO mice have improved glucose tolerance 
 To further test the effect of PDK2/PDK4 deficiency on glucose, glucose 
tolerance studies were conducted after feeding the mice the HSF diet for 27 weeks.  In 
agreement with our previous findings with chow diet fed mice [146], DKO mice had a 
better glucose tolerance than wild-type mice fed HSF diet (Figure 16A).  The area under 
the curve for DKO mice (8859 + 601 mg·dI-1·min-1; n=10) was significantly reduced 
compared to wild-type mice (11284 + 601 mg·dI-1·min-1; n = 10; P<0.02).  In contrast to 
the glucose tolerance, DKO mice responded similar to wild-type mice in the insulin 
tolerance test (Figure 16B) as evidenced by similar areas above the curve for DKO and 
wild-type mice (area above the curve of 19 ± 4 mg/dL ·min compared to 9 ± 5 for wild-
type mice; mean + SEM, n =6 per group, P > 0.05). 
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Figure 16.  Improved glucose tolerance without improved insulin sensitivity in DKO 
mice fed a HSF diet.  (A) Glucose tolerance tests (GTTs) were performed on wild-type 
and DKO mice fed the HSF diet for 27 weeks.  WT, n = 8; DKO, n = 8.  (B) Insulin 
tolerance tests (ITTs) were performed on wild-type and DKO mice fed the HSF diet for 
28 weeks.  WT, n = 8; DKO, n = 8.  All values are the mean ± S.E.M.  * P < 0.05 relative 
to wild-type mice determined by Student’s t test.  
 
Insulin levels were similar between DKO (13 ± 2 µU/mL, n = 5) and wild-type 
mice (16 ± 1 µU/mL, n = 5, P > 0.05) at 12 weeks. At 30 weeks, insulin levels were 
greatly increased in both groups of mice but insulin levels were found lower in DKO 
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mice compared to wild-type mice, leading to reduced HOMO-IR scores for DKO mice 
suggesting greater insulin sensitivity (Table 5). 
 
Table 5.  Blood metabolic parameters of wild-type (WT) and DKO mice.  Mice were 
fasted for 12 h.  * P < 0.05 compared to wild-type mice. Values are the mean ± S.E.M. 
with n = 4 mice per group. 
 
4.4.  DKO mice have lower blood concentrations of gluconeogenic substrates but 
higher levels of ketone bodies   
To test the hypothesis that PDK2/PDK4 deficiency reduces blood glucose by the 
lowering supply of gluconeogenic substrates needed for glucose production, serum levels 
of pyruvate and lactate, were measured (Table 5).  DKO mice had lower levels of 
pyruvate and lactate than wild-type mice (Table 5). In contrast, greater levels of β-
hydroxybutyrate, acetoacetate, and free fatty acids were found in the DKO mice fed the 
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HSF diet (Table 5).  Additionally, blood pH in the DKO mice were significantly reduced 
compared to wild-type mice.  High levels of ketone bodies in conjunction with decline in 
pH confirmed the presence of ketoacidosis in HSF diet fed DKO mice.  The dramatic rise 
of ketone bodies overwhelmed the capacity of the kidney for reabsorption of ketone 
bodies, resulting in larger excretion of  β-hydroxybutyrate in the urine of DKO mice (19 
+ 8 mmol/L DKO mice versus 1.6 + 0.2 mmol/L in wild-type mice after 24 h of fasting; n 
= 4 mice/group; P < 0.05).  The amount of blood nitrogen as measured by blood urea 
nitrogen (BUN) and creatinine levels were elevated in DKO mice (Table 5).  Levels of 
triacylglycerol (TG) and alanine transaminase (ALT), an enzyme that is released to the 
blood as a result of liver injury, were similar between DKO and wild-type mice (Table 5).  
 
4.5.  DKO mice suffer from fasting induced hypothermia 
In addition to suffering from ketoacidosis, DKO fed the HSF diet experienced 
severe hypothermia (24.9 ± 0.4 °C compared to 36.5 ± 0.3 °C in wild-type mice, n = 6 
mice per group, P < 0.05) after 24 hours of fasting, leading ultimately to their death.  
 
4.6.  Plasma essential amino acids and key gluconeogenic amino acids are reduced 
while citrulline is elevated in DKO mice   
Amino acid analysis was performed to determine whether gluconeogenic or 
ketogenic amino acids were altered in DKO mice.  Alanine, a key gluconeogenic amino 
acid, was reduced in DKO mice both in the fed and fasted state (Table 6).  
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Fed State                              24 h Fasted State
WT                 DKO                    WT                  DKO
Asn 110 ± 7           86 ± 14*                119 ± 22         115 ± 20
His              95 ± 4             81 ± 7*                  187 ± 32         168 ± 35
Ala              423 ± 131      282 ± 84*                777 ± 172      403 ± 89*
Pro             202 ± 13        153 ± 13*                229 ± 45        173 ± 25
Thr 235 ± 9          109 ± 13*                370 ± 52        476 ± 94
Tyr             22 ± 1             22 ± 1                    51 ± 5            45 ± 7
Met            136 ± 5           88 ± 6*                   212 ± 49        147 ± 38
Phe 43 ± 1            37 ± 2*                    111 ± 18        84 ± 11
Val             359 ± 25         258 ± 8*                  415 ± 53        831 ± 275*
Ile              141 ± 14          91 ± 2*                   169 ± 25        353 ± 125*
Leu 269 ± 24         188 ± 7*                  529 ± 96       834 ± 94*    
Lys            674 ± 14         458 ± 11*                990 ± 277     885 ± 272
Cit             107 ± 2           123 ± 13                  120 ± 20      199 ± 32*                 
 
Table 6.  Plasma amino acid levels in WT and DKO mice.  Amino acid levels are 
given in nmol/mL.  Blood was obtained for analysis in the fed state (9:00 a.m.) and after 
24 hr fast (6:00 p.m.).  * P < 0.05 compared to wild-type mice.  Values are the mean ± 
S.E.M. with n = 6 mice per group except for n = 4 wild-type mice in the fed state.   
 
Branched chain amino acids (valine, isoleucine, and leucine), were lower in DKO 
mice compared to wild-type mice in the fed state, whereas in the fasted state the DKO 
mice showed elevated amount of these amino acid.  Lysine, another ketogenic amino 
acid, was reduced in the fed state but not in the fasted state in DKO mice (Table 6).  
Amino acid analysis also revealed that essential amino acids were lowered in the fed state 
and unchanged except for BCAAs in the fasted state in DKO mice.  The decrease in 
essential amino acids in the fed state may be associated with increased protein synthesis, 
suggesting that PDK2/PDK4 deficiency promotes protein synthesis.  Furthermore, levels 
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of citrulline, an intermediate in the urea cycle, was increased in DKO mice after 24 hr 
fasting (Table 6).  In the fed state, however, citrulline levels were similar between DKO 
and wild-type mice.  
 
4.7.  DKO mice exhibit reduced capacity to sustain exercise under fasting conditions 
We hypothesized that DKO mice would not tolerate exercise due to ketoacidosis. 
DKO mice were exercised on a motorized treadmill apparatus using a run-to-exhaustion 
protocol.  DKO mice fasted for 12 h exhibited a markedly reduced capacity to sustain 
running exercise, whereas the running capacity of wild-type mice modestly reduced 
between the fed and fasting conditions (Figure 17).  Serum levels of pyruvate, lactate, 
bicarbonate, β-hydroxybutyrate, and blood pH were similar in fed DKO and wild-type 
mice after exhaustion (Figure 17B - 17F).  In contrast, significant reductions in pyruvate, 
lactate, bicarbonate, and blood pH occurred in fasted DKO mice compared to wild-type 
mice after exhaustion.  These findings suggest that sustaining exercise capacity under 
fasting conditions depend upon the presence of PDK2 and PDK4 to prevent ketoacidosis 
and prolong exercise endurance. 
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Figure 17.  Effect of exercise on wild-type and DKO mice fed a HSF diet.  (A) Run 
time, defined as the time point when mice were unable to run any longer, was determined 
in wild-type and DKO mice fed a HSF diet for 16 weeks.  Half of the mice in each group 
were fasted for 12 h and the remaining were in the fed state followed by exercise 
assessment.  Serum pyruvate (B), lactate (C), blood pH (D), blood bicarbonate (E), and 
serum β-hydroxybutyrate (F) were monitored after exercise.  All values are the mean ± 
S.E.M. with WT, n = 10; DKO, n = 10. * P < 0.05 relative to wild-type mice in the fasted 
state determined by Student’s t test. 
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4.8.  DKO mice exhibit hypothermia and ketoacidosis when fed a ketogenic diet 
 We hypothesized that ketogenic conditions induced by a high-fat/low-
carbohydrate intake state would lower blood glucose levels and provoke ketoacidosis and 
hypothermia as occurs under fasting conditions.  To examine this possibility, 8-week old 
wild-type and DKO mice were fed a low carbohydrate/high fat diet (0.4% carbohydrate, 
90.5% fat, and 9.1% protein from calories) or high carbohydrate/high fat diet (25.5% 
carbohydrate, 58.0 % fat, and 16.4 protein).  On the ketogenic diet, wild-type mice 
exhibited lower blood glucose compared to wild-type mice fed HC/HF diet while DKO 
mice experienced severe hypoglycemia compared to HC/HF fed DKO mice (Figure 
18A). Additionally, DKO mice on the ketogenic diet exhibited lower body temperature 
(Figure 18B), whereas wild-type and DKO mice maintained body temperatures at 37 °C 
on the HC/HF. 
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Figure 18.  Ketogenic diet induces hypoglycemia, hypothermia and ketoacidosis in 
DKO mice.  Blood glucose levels (A) and body temperature (B) were determined at 0, 1, 
and 2 d after addition of a high saturated fat diet (HFD) and ketogenic diet (KGD).  WT 
on HFD, n = 8; DKO on HFD, n = 8; WT on KGD, n = 8; DKO on KGD, n = 8. Serum 
β-hydroxybutyrate (C) and blood pH (D) were determined after 2 d of feeding with HSD 
and KGD. WT on HFD, n = 8; DKO on HFD, n = 8; WT on KGD, n = 8; DKO on KGD, 
n = 8. All values are the mean ± S.E.M. * P < 0.05 relative to wild-type mice on the 
HFD;  #  P < 0.05 relative to wild-type mice on the KGD determined by Student’s t test.  
 
Blood β-hydroxybutyrate levels were highly elevated (Figure 18C) while blood 
pH significantly reduced in DKO mice fed the ketogenic diet (Figure 18D).  Blood 
alanine transaminase (ALT) levels were reduced in DKO mice (41 ± 5 U/L, n = 12) 
compared to wild-type mice fed the high fat diet (64 ± 7 U/L; n = 12 mice per group, P < 
0.05).  DKO mice fed the ketogenic diet had lower ALT levels (23 ± 9 U/L, n = 12) than 
wild-type mice (43 ± 10 U/L, n = 12, P < 0.05).  These data indicated that regulation of 
blood glucose levels, ketone bodies, and thermogenesis mediated by PDK2 and PDK4 is 
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essential for fuel usage not only under fasting conditions but when mice are fed a high-
fat/low-carbohydrate diet.  
 
4.9.  Rate of glucose production is reduced in DKO mice 
 To test the hypothesis that PDK2/PDK4 regulates blood glucose levels in fasted 
state by controlling the rate of glucose production through substrate supply, stable-
isotope-based metabolic flux measurements were utilized to measure in vivo glucose 
production rates.   
 
 
 
 
 
 
Figure 19.  Rate of glucose production is reduced in DKO mice fed a HSF diet. 
Glucose production rate in wild-type and DKO after 18 h fast was determined using 
constant infusion of [U-13C6]glucose. WT, n = 4; DKO, n = 4.  The number following m 
indicates the number of 13C each molecule contains. WT, n = 4; DKO, n = 4.  All values 
are the mean ± S.E.M. * P < 0.05 relative to wild-type mice determined by Student’s t 
test.  
As expected, glucose production rate was reduced two fold in DKO mice (Figure 
19), suggesting that that rate of gluconeogenesis is limited by reduced supply of 
gluconeogenic substrates in the DKO mice.  Furthermore, protein level of a key 
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regulatory enzyme for gluconeogenesis, phosphoenolpyruvate carboxylase (PEPCK), was 
measured to determine whether an alteration in the amount of this enzyme was 
responsible for the lower blood glucose levels in DKO mice.  Protein levels of PEPCK 
were similar in the fasted livers of DKO and wild-type mice (Figure 20). 
PEPCK
β-Tubulin
WT                  DKO
 
 
Figure 20.  Expression of key gluconeogenic enzyme is not altered in the liver of 
DKO mice.  Protein levels of phosphoenolpyruvate carboxylase (PEPCK) and β-tubulin 
were determined in the liver obtained from 12 h fasted wild-type and DKO mice. WT, n 
= 4; DKO, n = 4.  
 
4.10.  DKO mice synthesize more but oxidize less ketone bodies 
We hypothesized that PDK2/PDK4 regulates ketone body levels by influencing 
the rate of ketone body production in the liver.  To test this hypothesis, metabolic flux 
analysis with stable isotope labeled β-hydroxybutyrate was conducted.  Measurements of 
β-hydroxybutyrate turnover rate using [U-13C4]β-hydroxybutyrate revealed a 30 % 
increase in β-hydroxybutyrate production rate in DKO mice (Figure 21A).  
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Figure 21.  Rate of β-hydroxybutyrate production is increased in DKO mice fed a 
HSF diet.  (A) β-hydroxybutyrate production rate in wild-type and DKO after 18 h fast 
was determined using constant infusion of [U-13C4]β-hydroxybutyrate. WT, n = 4; DKO, 
n = 4.  (B) Enrichment of β-hydroxybutyrate was produced from β-hydroxybutyrate in 
wild-type and DKO mice using constant infusion of [U-13C4]β-hydroxybutyrate.  The 
number following m indicates the number of 13C each molecule contains. WT, n = 4; 
DKO, n = 4.  All values are the mean ± S.E.M. * P < 0.05 relative to wild-type mice 
determined by Student’s t test.  
 
Additionally, the ratio of m2/m4 β-hydroxybutyrate which reflects the ratio of 
labeled acetyl-CoA (m2) to β-hydroxybutyrate (m4) was elevated by 2.5 fold in DKO 
mice (Figure 21B).  These findings suggests greater rate of re-cycling the ketone bodies 
by pseudo ketogenesis, presumably because of the high ketone body concentrations in the 
DKO mice.  
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To evaluate whether ketone body oxidation was altered in DKO mice, diaphragms 
from 20 weeks HSF diet fed DKO and wild-type mice were incubated with [3-14C]β-
hydroxybutyrate followed by collection of 14CO2.   
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Figure 22.  Ketone body oxidation is reduced in the diaphragms obtained from 
DKO mice.  (A) Rate of β-hydroxybutyrate oxidation, measured by 14CO2, was 
determined in hemi-diaphragms incubated with [3-14C]β-hydroxybutyrate.  Diaphragms 
were obtained from WT, n = 10; DKO, n = 10. Pyruvate release (B) and Lactate release 
(C) were determined in hemi-diaphragms incubated with [3-14C]β-hydroxybutyrate. 
Diaphragms were obtained from WT, n = 10; DKO, n = 10.  All values are the mean ± 
S.E.M. * P < 0.05;  ** P < 0.01 relative to wild-type mice determined by Student’s t test.  
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Beta-hydroxybutyrate oxidation rate, measured by 14CO2 production, was 72% 
less in diaphragms from DKO mice relative in diaphragms from wild-type mice (Figure 
22A). Furthermore, pyruvate (Figure 22B) and lactate release (Figure 22C) were 58% 
less respectively in diaphragms from DKO mice relative to diaphragms from wild-type 
mice.  Since ketone body oxidation has been shown to inhibit glucose oxidation, we 
determined glucose oxidation rates in diaphragms obtained from 16 weeks HSF fed DKO 
mice and wild-type mice by incubating with [U-14C] glucose followed by collection of 
14CO2.   
 
Figure 23.  Glucose oxidation is not altered in the diaphragms obtained from DKO  
mice. (A) Rate of glucose oxidation, measured by 14CO2, was determined in hemi-
diaphragms incubated with [U-14C6] glucose.  Diaphragms were obtained from WT, n = 
10; DKO, n = 10. Pyruvate release (B) and Lactate release (C) were determined in hemi-
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diaphragms incubated with [U-14C6] glucose.  Diaphragms were obtained from WT, n = 
10; DKO, n = 10.  All values are the mean ± S.E.M. ** P < 0.01 relative to wild-type 
mice determined by Student’s t test.  
 
Glucose oxidation rate, measured by 14CO2 production, was 46% greater in 
diaphragms from DKO mice relative from wild-type mice (Figure 23A).  Pyruvate release 
(Figure 23B) and lactate release (Figure 23C) were reduced 2 fold in diaphragms from DKO 
mice relative to wild-type mice. These findings suggest that PDK2/PDK4 deficiency 
increases levels of ketone bodies by enhancing ketone body production and suppressing 
ketone body oxidation.  In contrast, PDK2/PDK4 deficiency decreases blood glucose levels 
by decreasing glucose production and reducing glucose oxidation.  
 
4.11.  DKO mice oxidize less fatty acids 
Using indirect calorimetry, we determined locomotor activity,  the rate of oxygen 
consumption, energy expenditure, and fatty acid oxidation during 24 h fasting in 30 weeks of 
HSF fed DKO and wild-type mice (Figure 24).  Locomotor activity was greater in DKO and 
wild-type mice at night consisting of the first 12 hrs of fasting (Figure 24A).  At day time, 
locomotor activity was greatly reduced in both groups of mice but DKO mice remained less 
active than wild-type mice as fasting prolonged.  Rate of oxygen consumption (Figure 24B) 
were similar between DKO and wild-type mice during the first 12 h of fasting  but  both vital 
parameters for DKO mice started to rapidly decline after 13 h of fasting.  Energy expenditure 
(Figure 24C) and fatty acid oxidation rates (Figure 24D) were not different between wild-
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type and DKO mice during the first 11 h while progressively reduced for DKO mice as the 
fasting continued, reaching a dangerously low plateau at 18 hrs of fasting.  
 
 
Figure 24.  Rates of oxygen consumption, carbon dioxide production, energy 
expenditure, and fatty acid oxidation are reduced in HSF diet fed DKO mice in the 
fasted state.  Rate of Locomotor activity (A), oxygen production (B), energy expenditure 
(C), and fatty acid oxidation (D) were determined by TSE indirect calorimetry systems.  
Each parameter was recorded 6 times/h and then averaged to give hourly rates.  WT, n = 
8; DKO, n = 8.  All values are the mean ± S.E.M.  * P < 0.05 relative to wild-type mice 
determined by Student’s t test.   
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Body temperature taken after 24 h of fasting was dramatically lowered in DKO 
mice (24.7 ± 0.3 °C, n = 7 mice) relative to wild-type mice (37.0 ± 0.5 °C; n = 6 wild-
type mice; P < 0.01).  These findings suggest that reduction in metabolic rate results in 
less production of heat and therefore lower body temperature.  Since brown adipose 
tissue is a thermogenic tissue in which oxidation of fatty acids generates heat through 
uncoupling proteins (UCPs), we determined whether expression of UCPs were altered in 
the BAT obtained from hypothermic DKO mice (Figure 25A). 
UCP1
β-Tubulin
WT DKO
BAT
WT DKO
A
B
 
Figure 25.  Expression of uncoupling protein (UCP1) and morphology of brown 
adipose tissue (BAT) are not altered in DKO mice.  (A) Protein levels of UCP1 and β-
tubulin of wild-type and DKO mice were determined by western blot analysis in the BAT 
obtained after 24 h fasting. WT, n = 4; DKO, n = 4.  (B)  Microscopic photographs 
demonstrating histological appearance of BAT of wild-type and DKO mice fed a high 
HSF diet for 30 weeks.  BAT were obtained from 24 hr fasted wild-type and DKO mice. 
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Tissue sections were stained with H&E stain.  The material stained white corresponds to 
fat droplets.  
 
The protein levels of UCP1 in the BAT did not differ between wild-type and 
DKO mice (Figure 26A).  During 24 h of fasting when DKO mice have lower body 
temperature, the quantity and morphology of BAT are indistinguishable between wild-
type and DKO mice (Figure 25B).  
 
4.12.  PDK2/PDK4 deficiency suppresses levels of hepatic citric acid cycle 
intermediates 
We hypothesized that PDK2/PDK4 deficiency lowers pyruvate which in turn 
limits the formation of oxaloacetate needed for TCA cycle activity in the liver.  
Subsequently, acetyl-CoA is directed to the production of ketone bodies instead of 
oxidized by the citric acid cycle to CO2 and water.  To test this hypothesis, levels of 
pyruvate, oxaloacetate and other citric acid cycle intermediates were measured in the 
liver of wild-type and DKO mice fed HSF for 30 weeks.  In the fed state, liver 
concentrations of pyruvate (0.08 ± 0.01 µmol/g in DKO mice compared to 0.10 ± 0.03 
µmol/g in wild-type mice, n = 6 DKO mice; n = 5 wild-type mice; P > 0.05) and 
oxaloacetate (0.04 ± 0.02 µmol/g in DKO mice compared to 0.03 ± 0.01 µmol/g in wild-
type mice; n = 5 mice per group: P > 0.05) were similar between the wild-type and DKO.  
In the fasted state, on the other hand, oxaloacetate levels were reduced by 2 fold in the 
liver of DKO mice relative to wild-type mice (Table7).  Measured oxaloacetate levels 
were similar to calculated oxaloacetate levels based on the malate dehydrogenase 
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equilibrium constant (Table 7).  Since oxaloacetate is essential for citric acid cycle 
activity, level of malate, citrate, and α-ketoglutarate were determined in the liver of DKO 
and wild-type mice (Table 7).  Malate concentration was not different in the liver of DKO 
and wild-type mice (Table 7) whereas the concentrations of citrate and α-ketoglutarate 
were lower in DKO mice. 
Measurement WT  DKO
Pyruvate 0.047 + 0.007        0.010 + 0.003*
OAA measured                       0.015 ± 0.002        0.009 ± 0.002*
OAA calculated                      0.012 ± 0.002         0.004 ± 0.003
Malate 0.35 ± 0.06             0.26 ± 0.1
Citrate                                     0.26 ± 0.04             0.13 ± 0.02*       
α-ketoglutarate 0.016 ± 0.001         0.011 ± 0.001*
ATP                                         2.4 ± 0.1                2.25 ± 0.07
ADP                                        1.3 ± 0.1                1.14 ± 0.04*
AMP                                        0.47 ± 0.05            0.41 ± 0.02
Lactate 0.34 + 0.05            0.20 + 0.05*  
β-Hydroxybutyrate (HB) 1.6 ± 0.1                 4.5 ± 0.4*
Acetoacetate (AcAc) 0.26 ± 0.06             1.21 ± 0.05*
[Lactate]/[Pyruvate]              8 ± 1                       32 ± 9*
[HB]/[AcAc]  5 ± 1                      3.7 ± 0.02*
 
Table 7.  Liver metabolic parameters of wild-type (WT) and DKO mice.  Metabolites 
are given in units of µmol/g tissue.  Mice were fasted for 12 h.  * P < 0.05 compared to 
wild-type mice. Values are the mean ± S.E.M. with n = 6 mice per group. 
 
These data suggest that PDK2/PDK4 deficiency reduces oxaloacetetate 
concentrations, as well as of the citric acid cycle intermediates.  No differences in hepatic 
ATP and AMP concentrations were found between wild-type and DKO mice while ADP 
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was reduced in the liver of DKO mice (Table 7).  Furthermore, reduction of hepatic 
pyruvate resulted not only in suppression of oxaloacetate but as well in suppression of 
lactate.  The lactate/pyruvate ratio was elevated in the liver of DKO mice.  In contrast, 
the β-hydroxybutyrate levels were increased by two fold while acetoacetate levels were 
increased 5 fold in the liver of DKO mice, yielding a reduced hepatic β-
hydroxybutyrate/acetoacetate ratio. 
 
4.13.  OAA  evels are reduced in the skeletal muscle of DKO mice 
 Since oxaloacetate levels were reduced in the liver DKO mice, we investigated 
whether low pyruvate concentrations in DKO mice may limit the formation of 
oxaloacetate in peripherial tissues, shunting acetyl-CoA away from citric acid cycle.  As 
anticipated pyruvate and lactate levels were reduced in the skeletal muscle of DKO mice 
(Table 8).  
Measurements WT                      DKO
Lactate                                  1.8 ± 0.3                 0.7 ± 0.1*
Pyruvate 0.14 ± 0.05            0.05 ± 0.01*
Malate 0.3 ± 0.1                0.08 ± 0.03* 
OAA 0.06 ± 0.02            0.022 ± 0.003*
ATP                                       4.8 ± 0.2                3.4 ± 0.2*
ADP                                       0.5 ± 0.1                0.3 ± 0.1
AMP                                      0.06 ± 0.01            0.03 ± 0.01
 
Table 8.  Effect of PDK2/PDK4 deficiency on muscle metabolite levels.  Metabolites 
are given in units of µmol/g of wet weight tissue.  Mice were fasted for 12 hrs. * P < 0.05 
compared to wild-type mice. Values are the mean ± S.E.M. with n = 5 mice per group. 
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As a consequence of low pyruvate, oxaloacetate levels were reduced remarkably 
in the skeletal muscle.  Additionally, malate concentrations were reduced in DKO mice. 
Surprisingly, muscle ATP levels were significantly lowered with no differences in ADP 
and AMP in the muscle of DKO mice fasted for 12 h.  Similar reduced ATP levels were 
also found in the muscle of DKO mice (3.6 ± 0.3 µmol/g; means ± S.E.M.; n = 6 mice) 
and wild-type mice (5.4 ± 0.3 µmol/g; n = 6 mice; P < 0.05) after 24 h of fasting.  These 
data indicate that PDK2 and PDK4 plays a pivotal role in supplying pyruvate for 
pyruvate carboxylase to produce oxaloacetate needed to initiate TCA cycle activity for 
ATP production during starvation.   
 
4.14.  OAA levels are reduced in the liver of DKO mice fed the ketogenic diet 
 We hypothesized that a low carbohydrate-high fat diet such as the ketogenic diet 
lowers pyruvate levels which in turn will limit the production of oxaloacetate for TCA 
cycle activity and glucose production.  
High Fat Diet                                              Ketogenic Diet
WT                        DKO                 WT                        DKO
Pyruvate 0.04 ± 0.01             0.015 ± 0.002*          0.016 ± 0.005            0.008 ± 0.002#
Lactate                       0.8 ± 0.1                0.4 ± 0.1*                  0.16 ± 0.05                0.10 ± 0.04#
β-hydroxybutyrate 0.19 ± 0.05            0.42 ± 0.05*              1.5 ± 0.2                    2.25 ± 0.2#
Oxaloacetate 0.014 ± 0.003        0.012 ± 0.003            0.017 ± 0.002            0.010 ± 0.002#
 
Table 9.  Liver metabolites of WT and DKO mice fed a high fat diet and a ketotic 
diet.  Metabolites are given in units of µmol/g tissue.  Mice were killed in the fed state.  
* P < 0.05 compared to wild-type mice on high fat diet. # P < 0.05 compared to wild-type 
mice on ketogenic diet. Values are the mean ± S.E.M. with n = 12 mice per group. 
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Hepatic pyruvate and lactate concentrations were reduced in wild-type mice fed 
the ketogenic diet compared to wild-type fed the high fat diet (Table 9).  But pyruvate 
and lactate levels were reduced in the liver of DKO mice on both diets compared to wild-
type mice.  Similar to blood concentrations, β-hydroxybutyrate levels were elevated in 
the liver of DKO fed either diet and in wild-type mice fed the ketogenic diet compared to 
wild-type mice fed the high fat diet.  The concentrations of oxaloacetate was reduced in 
DKO mice fed the ketogenic diet (Table 9).  These data suggest that PDK2 and PDK4 are 
essential in conserving pyruvate needed for pyruvate carboxylase to produce oxaloacetate 
when the dietary supply of pyruvate is lowered by low carbohydrate-high fat diet.  As a 
consequence of low oxaloacetate, glucose synthesis is reduced and ketogenesis in 
increased resulting in hypoglycemia and ketoacidosis in DKO mice fed a low 
carbohydrate/high fat diet.  
  
5.  Discussion 
This study shows that PDK2/PDK4 deficiency partially prevents high-fat diet 
induced hyperglycemia, adiposity, and fasting induced hepatic steatosis.  Wild-type mice 
maintained for 30 weeks on a high saturated fat diet were grossly obese, hyperglycemia, 
hyperinsulinaemic, glucose intolerant, and insulin resistant.  PDK2/PDK4 double 
knockout mice fed the same diet for the same length of time gained less weight, remained 
euglycemic, and were less glucose intolerant than wild-type mice.  Although 
PDK2/PDK4 deficiency attenuated some of the negative effects caused by a high 
saturated fat diet, it induced ketoacidosis during fasting.  
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PDK deficiency is believed to lower fasting blood glucose levels by decreasing 
the supply of substrates needed for gluconeogenesis [67].  Consistent with this 
hypothesis, the blood concentrations of pyruvate, alanine, and lactate were reduced in 
PDK2/PDK4 double knockout mice.  Since the availability of gluconeogenic substrates is 
limited in PDK2/PDK4 deficient mice, DKO mice synthesize glucose at a lower rate than 
wild-type mice as shown in this study by metabolic flux analysis with [U-13C6]glucose. 
The euglycemia of DKO mice is due to reduced rate of glucose production. 
Hyperglycemia in wild-type mice is due to increased rate of glucose production.  
Furthermore, no difference in the expression of PEPCK, which can limit the rate of 
gluconeogenesis in some situations [146], was found between DKO and wild-type mice.  
These findings suggest that altered expression of gluconeogenic enzyme is not 
responsible for euglycemia in DKO mice.  These findings are consistent with recent 
studies that demonstrated that gluconeogenic enzymes are not elevated in hyperglycemic 
patients with type 2 diabetes and in 2 rodent models of hyperglycemia [153].  Our work 
suggests that hyperglycemia is dictated by the rate of glucose production which in turn 
depends on substrate supply regulated by the PDKs.  We believe that induction of PDK2 
and PDK4 in type 2 diabetic patients promotes the phosphorylation and inactivation of 
PDC to conserve gluconeogenic substrates, leading to enhanced substrate availability and 
increased glucose production.  Enhanced glucose synthesis contributes to elevation of 
blood glucose levels resulting in hyperglycemia.   
Although our study supports the idea that PDK inhibition may serve as a good 
target for treatment for type 2 diabetic patients, double deficiency of PDK2 and PDK4 
greatly increases blood ketone body levels.  Although this is only observed in the fasted 
 93 
state, it is undesirable effect of PDK deficiency because it invokes ketoacidosis, which 
can be fatal.  Stable isotope metabolic flux analysis with [U-13C4]β-hydroxybutyrate 
indicated DKO mice synthesize ketone bodies at a higher rate than wild-type mice while 
in vitro incubation studies with [3-14C]β-hydroxybutyrate indicated that DKO mice 
oxidize ketone bodies at a lower rate than wild-type mice.  It appears, therefore, that both 
an increase in ketogenesis and a decrease in ketolysis contribute to the accumulation of 
ketone bodies in the blood of DKO mice.  We hypothesized that reduced supply of three 
carbon compounds limits availability of oxaloacetate in the liver which directs acetyl-
CoA into ketone body formation instead of oxidation by the citric acid cycle.  Consistent 
with this hypothesis, oxaloacetate and citric acid cycle intermediates were reduced in the 
liver of DKO mice.  In the absence of PDK2 and PDK4, PDC is highly active to promote 
rapid oxidation of pyruvate, resulting in low pyruvate levels.  Pyruvate is needed for 
synthesis of oxaloacetate which in turn is essential for condensation with acetyl-CoA to 
form citrate to initiate the TCA cycle activity.  Low pyruvate levels limit oxaloacetate 
synthesis which in turn suppresses TCA cycle activity and shunts acetyl-CoA into ketone 
synthesis. Without citric acid cycle activity and without the enzymatic capacity for 
ketone body synthesis, extrahepatic tissues of DKO mice are unable to oxidize ketone 
bodies.  Furthermore, indirect calorimetric measurements indicated that DKO mice 
oxidize fatty acids at a lower rate than wild-type mice.  In the absence of oxaloacetate 
and reduced TCA cycle activity, complete oxidation of fatty acids is inhibited.  Inhibition 
of fatty acid and ketone body oxidation, results in less heat produced to maintain body 
temperature, provoking hypothermia in DKO mice. 
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Depletion of oxaloacetetate is responsible for the ketoacidotic and hypothermic 
phenotype of PDK2/PDK4 knockout mice.  Similar detrimental effects of oxaloacetate 
deficiency are also manifested in patients with pyruvate carboxylase (PC) deficiency, 
which is characterized by metabolic acidosis, ketosis, lactic acidemia, and delayed 
neurological development [103].  This disorder spans from the most severe (Type B) to 
less severe forms (Type A, C) [105].  Type B patients present with an elevated ratio of 
lactate to pyruvate (L/P) and reduced ratio of β-hydroxybutyrate to acetoacetate (B/A) 
ratios in contrast to those seen in patients with type A and type C.  Since these ratios are 
determined by the redox state of NAD+ in the cytoplasm and the mitochondria, 
respectively, it is apparent that the enzymatic capacity for the formation of OAA is a 
major determinant of the NAD+ redox state.  Reduced availability of oxaloacetate in the 
mitochondria as a result of PC deficiency decreases the activity of the malate-aspartate 
shuttle that moves reducing equivalents from the cytoplasm to the mitochondrial matrix 
space.  As a result, the ratio of NADH to NAD+ is high in the cytoplasm, favoring the 
conversion of pyruvate to lactate and resulting in a high L/P ratio.  Less transport of 
NADH into the mitochondria leads to a low ratio of NADH to NAD+ ratio in the 
mitochondrial matrix space, resulting in less conversion of acetoacetate to β-
hydroxybutyrate and a low B/A ratio [104].  Similar alterations in the L/P and B/A ratios 
occur in PDK2/PDK4 double knockout mice.  While lack of functional enzyme activity is 
responsible for low oxaloacetate levels in PC deficient patients, lack of substrate 
(pyruvate) is responsible for reduced pyruvate carboxylase flux in PDK deficient mice.  
Not surprisingly, therefore, the phenotype of PDK2/PDK4 double knockout mice 
resembles that of type B PC deficient patients.    
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This study demonstrates that the PDKs are essential in regulating pyruvate 
carboxylase flux by substrate supply to maintain blood glucose levels, ketone bodies, and 
body temperature.  The PDKs phosphorylate the PDC to conserve pyruvate for glucose 
synthesis and for oxaloacetate formation which is needed for TCA cycle activity.  
Disruption of this control mechanism mediated by the PDKs has detrimental effects 
resulting in ketoacidosis and hypothermia.  
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GLOBAL CONCLUSION 
The primary goal of my research was to establish the role of pyruvate 
dehydrogenase kinase (PDKs) in regulating glucose and ketone body metabolism. Our 
work determined that PDK2/PDK4 inactivates the pyruvate dehydrogenase complex 
(PDC) by phosphorylation to conserve substrate supply for the liver for glucose 
production.  Furthermore, inactivation of PDC by the PDKs preserves pyruvate for 
oxaloacetate synthesis for TCA cycle activity.  Proper TCA cycle activity in the liver 
promotes acetyl-CoA oxidation and prevents the diversion of acetyl-CoA into ketone 
bodies synthesis.  Inhibition of PDK2/PDK4 disrupts this control mechanism and results 
in less glucose production and increased ketone body synthesis.  Consequently, 
PDK2/PDK4 deficient mice experience lower blood glucose levels and increased ketone 
bodies.  
My work also explored whether the glucose lowering effects of PDK inhibition 
would be maintained in a diet induced diabetic animal model.  Inhibition of PDK2 and 
PDK4 in mice fed a high fat diet improved insulin sensitivity, decreased adiposity, 
reduced fat accumulation in the liver, and prevented hyperglycemia.  These desirable 
effects of knocking out PDKs provide convincing evidence that PDK inhibition is a good 
target for treatment of type 2 diabetes.  Nevertheless, my study revealed that the use of 
PDK inhibitors is accompanied by a potentially serious side effect.  PDK2/PDK4 
inhibition can induce severe ketoacidosis and hypothermia.   
Currently, a synthetic PDK inhibitor, dichloroacetate (DCA) has been used 
experimentally to reduce growth of solid tumors in non-small cell lung cancer, 
glioblastoma, breast, endometrial and prostate cancer [154].  Glioblastoma patients have 
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been treated with DCA for 15 months without experiencing any toxicity of the 
compound, at least according to the investigators who carryout out this study [155].  
Although based on my work with the PDK2/PDK4 deficient mice, I predict that patients 
treated with large doses of DCA may experience ketoacidosis and hypothermia.  In the 
future, it may become important to design new inhibitors that partially inhibit the PDKs 
without causing ketoacidosis.  Since complete inhibition of PDK2 and PDK4 results in 
severe ketoacidosis in the PDK2/PDK4 double knockout mice, we would predict that 
partially inhibiting the PDKs would not provoke such severe phenotype.  Additionally, 
we believe that designing a liver specific PDK inhibitor will have glucose lowering 
effects without inducing ketoacidosis.  
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